☒
|
ANNUAL REPORT PURSUANT TO SECTI ON 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
|
Nevada
|
|
46-3312262
|
(State or other jurisdiction of
incorporation or organization)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|||
Large accelerated
filer ☐
|
|
Accelerated filer ☐
|
|
|
Non-Accelerated
filer ☐
(Do not check if a smaller reporting
company)
|
|
Smaller Reporting Company ☒
|
|
TABLE OF
CONTENTS
|
|
|
Page No.
|
|
|
|
|
||
1
|
||
6
|
||
6
|
||
6
|
||
6
|
||
6
|
||
|
|
|
|
||
7
|
||
8
|
||
8
|
||
17
|
||
17
|
||
18
|
||
18
|
||
19
|
||
|
|
|
|
||
19
|
||
26
|
||
27
|
||
29
|
||
31
|
||
|
|
|
|
||
32
|
||
|
33
|
|
|
34
|
●
|
the quality of outcomes for medical conditions;
|
●
|
acceptance by surgeons and the medical device market
generally;
|
●
|
ease of use and reliability;
|
●
|
technical leadership and superiority;
|
●
|
effective marketing and distribution;
|
●
|
speed to market; and
|
●
|
product price and qualification for coverage and
reimbursement.
|
●
|
Class
I: general controls, such as labeling and adherence to quality
system regulations;
|
●
|
Class
II: special controls, pre-market notification (often referred to as
a 510(k) application), specific controls such as performance
standards, patient registries, post market surveillance,
additional controls such as labeling and adherence to quality
system regulations; and
|
●
|
Class III: special controls and approval of a pre-market approval
(“PMA”) application.
|
●
|
the
FDA Quality Systems Regulation ("QSR"), which governs, among other
things, how manufacturers design, test, manufacture, exercise
quality control over, and document manufacturing of their
products;
|
●
|
labeling
and claims regulations, which prohibit the promotion of products
for unapproved or “off-label” uses and impose other
restrictions on labeling; and
|
●
|
the Medical Device Reporting regulation, which requires reporting
to the FDA of certain adverse experiences associated with use of
the product.
|
|
2016
|
|
By Quarter
|
High
|
Low
|
First
|
$1.51
|
$0.85
|
Second
|
2.25
|
1.01
|
Third
|
1.70
|
1.25
|
Fourth
|
1.73
|
1.33
|
●
|
Level
1: Quoted prices (unadjusted) in active markets that are accessible
at the measurement date for identical assets or
liabilities;
|
●
|
Level
2: Quoted prices in active markets for similar assets or
liabilities or observable prices that are based on inputs not
quoted on active markets, but corroborated by market data;
and
|
●
|
Level 3:
Unobservable inputs or valuation techniques that are used when
little or no market data is available.
|
Grant
date
|
January 6
|
August 17
|
November 10
|
Weighted
fair value of options granted as of December 31, 2016
|
$0.67
|
$0.91
|
$1.06
|
Expected
term (years)
|
6
|
6
|
6
|
Risk-free
interest rate
|
1.82%
|
1.28%
|
1.74%
|
Volatility
|
83%
|
75.55%
|
76.67%
|
Dividend
yield
|
None
|
None
|
None
|
Operating Expenses:
|
2016
|
2015
|
General
and administrative
|
$4,872,626
|
$4,561,470
|
Sales
and marketing
|
391,698
|
101,772
|
Research
and development
|
1,126,535
|
867,822
|
Depreciation
and amortization
|
11,267
|
6,498
|
Impairment
of goodwill
|
6,455,645
|
--
|
Total operating expenses
|
12,857,771
|
5,537,562
|
|
|
|
Operating
Loss
|
(12,857,771)
|
(5,537,562)
|
|
|
|
Other Expenses:
|
|
|
Interest
expense
|
455,304
|
46,259
|
Total Other Expenses
|
455,304
|
46,259
|
|
|
|
Loss from Continuing Operations
|
(13,313,075)
|
(5,583,821)
|
Discontinued Operations
|
|
|
Loss
from discontinued operations
|
477,497
|
939,256
|
Impairment
loss
|
1,584,048
|
--
|
Disposal
loss
|
852,864
|
--
|
Total Loss from Discontinued Operations
|
(2,914,409)
|
(939,256)
|
Net Loss
|
$(16,227,484)
|
$(6,523,077)
|
F-2
|
|
F-3
|
|
F-4
|
|
F-5
|
|
F-6
|
|
F-7
|
MEDOVEX CORP. AND SUBSIDIARY
|
||
CONSOLIDATED BALANCE SHEETS
|
||
|
|
|
|
December 31, 2016
|
December 31, 2015
|
Assets
|
|
|
Current Assets
|
|
|
Cash
|
$892,814
|
$1,570,167
|
Prepaid
expenses
|
364,822
|
169,253
|
Current
assets held for sale
|
--
|
35,509
|
Total Current Assets
|
1,257,636
|
1,774,929
|
Long Term Receivable
|
150,000
|
--
|
Property and Equipment, net of accumulated
depreciation
|
97,590
|
23,724
|
Deposits
|
2,751
|
2,751
|
Goodwill
|
--
|
6,455,645
|
Noncurrent assets held for sale
|
--
|
3,274,685
|
Total Assets
|
$1,507,977
|
$11,531,734
|
Liabilities and Stockholders' Equity
|
|
|
Current Liabilities
|
|
|
Interest
payable
|
$69,222
|
$76,712
|
Accounts
payable
|
225,725
|
278,309
|
Accrued
liabilities
|
459,800
|
100,317
|
Notes
payable, current portion
|
126,086
|
134,540
|
Short-term
note payable, net of debt discount
|
970,240
|
--
|
Total Current Liabilities
|
1,851,073
|
589,878
|
Long-Term Liabilities
|
|
|
Convertible
debt
|
--
|
753,914
|
Notes
payable, net of current portion
|
103,742
|
164,726
|
Deferred
rent
|
1,179
|
491
|
Total Long-Term Liabilities
|
104,921
|
919,131
|
Total Liabilities
|
1,955,994
|
1,509,009
|
Stockholders' (Deficit) Equity
|
|
|
Preferred
stock - $.001 par value: 500,000 shares
|
|
|
authorized,
no shares outstanding
|
--
|
--
|
Common
stock - $.001 par value: 49,500,000 shares authorized,
|
|
|
14,855,181
and 11,256,175 shares issued at December 31, 2016
and
December 31, 2015, respectively, 14,855,181 and
11,048,203
shares
outstanding at December 31, 2016 and December 31, 2015,
respectively
|
14,855
|
11,256
|
Additional
paid-in capital
|
25,898,054
|
20,164,911
|
Due
from stockholder
|
--
|
(20,000)
|
Accumulated
deficit
|
(26,360,926)
|
(10,133,442)
|
Total Stockholders' (Deficit) Equity
|
(448,017)
|
10,022,725
|
Total Liabilities and Stockholders' (Deficit) Equity
|
$1,507,977
|
$11,531,734
|
|
For the year ended
December 31,
|
|
|
2016
|
2015
|
|
|
|
Operating Expenses
|
|
|
General
and administrative
|
$4,872,626
|
$4,561,470
|
Sales
& Marketing
|
391,698
|
101,772
|
Research
and development
|
1,126,535
|
867,822
|
Depreciation
and amortization
|
11,267
|
6,498
|
Impairment
of goodwill
|
6,455,645
|
--
|
Total Operating Expenses
|
12,857,771
|
5,537,562
|
|
|
|
Operating Loss
|
(12,857,771)
|
(5,537,562)
|
|
|
|
Other Expenses
|
|
|
Interest
expense
|
455,304
|
46,259
|
Total Other Expenses
|
455,304
|
46,259
|
|
|
|
Loss from Continuing Operations
|
(13,313,075)
|
(5,583,821)
|
|
|
|
Discontinued Operations
|
|
|
Loss
from discontinued operations
|
477,497
|
939,256
|
Impairment
loss
|
1,584,048
|
--
|
Disposal
loss
|
852,864
|
--
|
Total Loss from Discontinued Operations
|
(2,914,409)
|
(939,256)
|
Net Loss
|
$(16,227,484)
|
$(6,523,077)
|
|
|
|
Basic
and diluted net loss per common share from continuing
operations
|
$(1.00)
|
$(0.51)
|
|
|
|
Basic
and diluted net loss per common share from discontinued
operations
|
(0.22)
|
(0.09)
|
|
|
|
Basic
and diluted net loss per common share
|
$(1.22)
|
$(0.60)
|
|
|
|
Basic
and diluted weighted average common shares outstanding
|
13,250,789
|
10,943,675
|
|
Common
Stock
|
Additional
|
Due From
|
Accumulated
|
Total
Stockholders' |
|
|
Shares
|
Amount
|
Paid-in
Capital
|
Stockholder
|
Deficit
|
Equity
|
Balance – December 31, 2014
|
9,172,480
|
$9,173
|
$10,106,841
|
$--
|
$(3,610,365)
|
$6,505,649
|
|
|
|
|
|
|
|
Issuance
of common stock to underwriters in January 2015
|
208,695
|
208
|
1,083,928
|
--
|
--
|
1,084,136
|
Value
of common stock to acquire Streamline on date of closing at $4.50
per share
|
1,875,000
|
1,875
|
8,435,625
|
--
|
--
|
8,437,500
|
Stock
based compensation
|
--
|
--
|
253,659
|
--
|
--
|
253,659
|
Issuance
of warrant to Steve
|
|
|
|
|
|
|
Gorlin
on November 9 2015
|
--
|
--
|
284,858
|
--
|
--
|
284,858
|
Receivable
portion of Note
|
|
|
|
|
|
|
of
convertible debt
|
--
|
--
|
--
|
(20,000)
|
--
|
(20,000)
|
Net
loss
|
--
|
--
|
--
|
--
|
(6,523,077)
|
(6,523,077)
|
Balance – December 31, 2015
|
11,256,175
|
$11,256
|
$20,164,911
|
$(20,000)
|
$(10,133,442)
|
$10,022,725
|
Conversion
of promissory note on January 25, 2016
|
552,041
|
552
|
1,071,961
|
--
|
--
|
1,072,513
|
Warrant
price modification on January 25, 2016
|
--
|
--
|
18,050
|
--
|
--
|
18,050
|
Warrant
price modification on February 16, 2016
|
--
|
--
|
7,670
|
--
|
--
|
7,670
|
Issuance
of common stock pursuant to private placement completed in April
2016
|
1,211,703
|
1,212
|
800,435
|
--
|
--
|
801,647
|
Issuance
of warrants pursuant to private placement completed in April
2016
|
--
|
--
|
374,623
|
--
|
--
|
374,623
|
Issuance
of common stock in exchange for consulting services in May
2016
|
37,500
|
38
|
47,962
|
--
|
--
|
48,000
|
Issuance
of common stock pursuant to private placement completed in August
2016
|
1,083,333
|
1,083
|
975,526
|
--
|
--
|
976,609
|
Issuance
of warrants pursuant to private placement completed in August
2016
|
--
|
--
|
323,391
|
--
|
--
|
323,391
|
Issuance
of common stock in exchange for consulting services in August
2016
|
60,000
|
60
|
76,740
|
--
|
--
|
76,800
|
Issuance
of warrants pursuant to loan completed in September
2016
|
--
|
--
|
135,971
|
--
|
--
|
135,971
|
Issuance
of common stock in exchange for consulting services in September
2016
|
83,000
|
83
|
124,417
|
--
|
--
|
124,500
|
Issuance
of common stock in December 2016 pursuant to conversion of
promissory note in January 2016
|
571,429
|
571
|
999,429
|
--
|
--
|
1,000,000
|
Repayment
of stockholder receivable
|
--
|
--
|
--
|
20,000
|
--
|
20,000
|
Stock
based compensation
|
--
|
--
|
776,968
|
--
|
--
|
776,968
|
Net
loss
|
--
|
--
|
--
|
--
|
(16,227,484)
|
(16,227,484)
|
Balance –
December 31, 2016
|
14,855,181
|
$14,855
|
$25,898,054
|
$--
|
$(26,360,926)
|
$(448,017)
|
|
Year Ended December 31,
|
|
|
2016
|
2015
|
Cash Flows from Operating Activities
|
|
|
Net
loss
|
$(16,227,484)
|
$(6,523,077)
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|
|
Depreciation
|
11,396
|
6,669
|
Amortization
of intangible assets
|
189,522
|
426,429
|
Amortization
of debt discount
|
357,297
|
38,770
|
Debt
conversion expense
|
68,694
|
--
|
Intangible
asset impairment loss
|
1,584,048
|
--
|
Goodwill
impairment loss
|
6,455,645
|
--
|
Disposal
loss
|
852,864
|
|
Stock
based compensation
|
776,968
|
253,659
|
Straight-line
rent adjustment
|
688
|
491
|
Common
stock issued for consulting services
|
249,300
|
--
|
Non-cash
directors fees
|
20,000
|
--
|
Adjustment
of fair value of warrant modification
|
25,720
|
--
|
Changes
in operating assets and liabilities, net of effects of acquisition
and disposition:
|
|
|
Deposits
|
--
|
(2,751)
|
Accounts
receivable
|
33,045
|
(33,045)
|
Prepaid
expenses
|
(128,400)
|
63,474
|
Accounts
payable
|
(52,584)
|
(164,144)
|
Interest
payable
|
(3,670)
|
76,712
|
Accrued
liabilities
|
359,483
|
(125,130)
|
Net Cash Used in Operating Activities
|
5,427,468
|
(5,981,943)
|
Cash Flows from Investing Activities
|
|
|
Acquisition
of Streamline, Inc., net of cash received
|
--
|
(1,152,291)
|
Disposition
of Streamline Inc.
|
500,000
|
--
|
Expenditures
for property and equipment
|
(85,133)
|
(7,059)
|
Net Cash Provided by (Used in) Investing Activities
|
414,867
|
(1,159,350)
|
Cash Flows from Financing Activities
|
|
|
Principal
payments under note payable obligation
|
(136,022)
|
(37,251)
|
Proceeds
from issuance of convertible debt
|
--
|
695,142
|
Proceeds
from issuance of common stock, net of offering costs
|
2,778,256
|
--
|
Proceeds
from issuance of warrants, net of offering costs
|
833,985
|
284,858
|
Proceeds
from issuance of short term debt
|
859,029
|
--
|
Proceeds
from issuance of common stock from underwriter’s
overallotment
|
--
|
1,084,136
|
Net Cash Provided by Financing Activities
|
4,335,248
|
2,026,885
|
Net
Decrease in Cash
|
677,353
|
(5,114,409)
|
Cash
- Beginning of period
|
1,570,167
|
6,684,576
|
|
|
|
Cash - End of period
|
$892,814
|
$1,570,167
|
Supplementary
Cash Flow Information
|
|
|
Cash
paid for interest
|
$11,469
|
$8,040
|
Non-cash investing and financing activities
|
|
|
Issuance
of common stock for acquisition of Streamline
|
$--
|
$8,437,500
|
Finance
agreement for insurance policy
|
66,582
|
76,581
|
Due
from shareholder for issuance of convertible debt
|
--
|
20,000
|
Repayment
of due from stockholder through forgone director fees
|
20,000
|
--
|
Issuance
of common stock for consulting services
|
249,300
|
--
|
Conversion
of note and accrued interest to common stock
|
1,072,513
|
--
|
Note
receivable from disposition of Streamline
|
150,000
|
--
|
Trademark
|
5
years
|
Developed
technology
|
7
years
|
●
|
Level
1: Quoted prices (unadjusted) in active markets that are accessible
at the measurement date for identical assets or
liabilities;
|
●
|
Level
2: Quoted prices in active markets for similar assets or
liabilities or observable prices that are based on inputs not
quoted on active markets, but corroborated by market data;
and
|
●
|
Level 3:
Unobservable inputs or valuation techniques that are used when
little or no market data is available.
|
|
Useful
Life
|
December
31,
2016
|
December
31,
2015
|
Furniture and
fixtures
|
5
years
|
$65,987
|
$17,100
|
Computers and
software
|
3
years
|
19,928
|
16,275
|
Leasehold
improvements
|
5
years
|
32,593
|
--
|
|
118,508
|
33,375
|
|
Less accumulated
depreciation and amortization
|
|
(20,918)
|
(9,651)
|
|
|
|
|
Total
|
|
$97,590
|
$23,724
|
Assets
acquired
|
|
Cash
|
$245,174
|
Inventory
|
1,878
|
Other
assets
|
165
|
Developed
technology
|
3,000,000
|
Trademark
|
700,000
|
Goodwill
|
6,455,645
|
|
|
Total assets
acquired
|
10,402,862
|
|
|
Liabilities
assumed
|
|
Accounts
payable
|
301,940
|
Accrued
liabilities
|
6,018
|
Notes
payable
|
259,938
|
|
|
Total
|
567,896
|
|
|
Net assets
acquired
|
$9,834,966
|
Grant
date
|
January
6
|
August
17
|
November
10
|
Fair
value of options granted during 2016
|
$0.67
|
$0.91
|
$1.06
|
Exercise
price
|
$0.95
|
$1.20
|
$1.58
|
Number
of options
|
214,900
|
320,000
|
210,000
|
Expected
term (years)
|
6
|
6
|
6
|
Risk-free
interest rate
|
1.82%
|
1.28%
|
1.74%
|
Volatility
|
83%
|
75.55%
|
76.67%
|
Dividend
yield
|
None
|
None
|
None
|
|
Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Term
(Years)
|
Outstanding at
12/31/2014
|
60,000
|
$2.50
|
8.8
|
|
|
|
|
Granted
|
320,000
|
$4.22
|
9.3
|
Exercised
|
--
|
--
|
--
|
Cancelled
|
--
|
--
|
--
|
Outstanding at
12/31/2015
|
380,000
|
$3.95
|
9.1
|
|
|
|
|
Granted
|
744,900
|
$1.24
|
9.52
|
Exercised
|
--
|
--
|
--
|
Cancelled
|
--
|
--
|
--
|
Outstanding at
12/31/2016
|
1,124,900
|
$2.15
|
9.0
|
Exercisable at
12/31/2016
|
523,725
|
$2.31
|
9.0
|
|
|
|
|
December 31,
2017
|
35,000
|
December 31,
2018
|
21,000
|
|
$56,000
|
December 31,
2017
|
2,600
|
December 31,
2018
|
800
|
|
$3,400
|
2017
|
61,000
|
2018
|
64,000
|
2019
|
45,000
|
|
$170,000
|
|
Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining Contractual
Life
|
Outstanding at
12/31/2014
|
1,474,783
|
$3.00
|
4.9
|
|
|
|
|
Issued
|
500,000
|
$1.825
|
5.0
|
Exercised
|
--
|
--
|
--
|
Expired
|
--
|
--
|
--
|
Outstanding at
12/31/2015
|
1,974,783
|
$2.86
|
4.0
|
|
|
|
|
Issued
|
1,530,064
|
$1.34
|
4.2
|
Exercised
|
--
|
--
|
--
|
Expired
|
--
|
--
|
--
|
Outstanding at
12/31/2016
|
3,504,847
|
$1.85
|
3.9
|
Exercisable at
12/31/2016
|
3,504,847
|
$1.85
|
3.9
|
Event
Description
|
Date
|
MDVX
Stock Price
|
Exercise Price of Warrant
|
Grant Date Fair Value
|
Life
of Warrant
|
Risk Free Rate of Return (%)
|
Annualized Volatility Rate (%)
|
Convertible
Note
|
11/9/15
|
$1.71
|
$2.20
|
$2.12
|
3
years
|
1.27
|
81.00
|
Modification
Agreement
|
1/25/16
|
$1.32
|
$2.00
|
$1.93
|
3
years
|
1.11
|
99.66
|
Modification
Agreement
|
2/16/16
|
$1.43
|
$1.825
|
$1.82
|
3
years
|
0.93
|
100.34
|
Private
Placement
|
4/19/16
|
$1.13
|
$1.30
|
$1.43
|
5
years
|
1.26
|
75.54
|
Private
Placement
|
4/29/16
|
$1.28
|
$1.30
|
$1.43
|
5
years
|
1.28
|
75.34
|
Private
Placement
|
8/5/16
|
$1.35
|
$1.52
|
$1.44
|
5
years
|
1.13
|
75.56
|
Private
Placement
|
8/16/16
|
$1.34
|
$1.52
|
$1.43
|
5
years
|
1.16
|
75.56
|
Short-Term
Loan
|
9/16/16
|
$1.58
|
$1.625
|
$1.58
|
3
years
|
0.91
|
75.75
|
|
December 31,
2015
|
Current Assets
|
|
Inventory
|
$1,878
|
Accounts
receivable
|
33,045
|
Prepaid
expenses
|
586
|
Total Current Assets Held for Sale
|
35,509
|
Property and Equipment, Net
|
1,114
|
Trademark, net
|
595,000
|
Developed Technology, net
|
2,678,571
|
Total Assets Held for Sale
|
$3,310,194
|
|
Year Ended December 31,
|
|
|
2016
|
2015
|
Revenues
|
$--
|
$33,045
|
Cost of Goods Sold
|
--
|
25,383
|
Gross Profit
|
--
|
7,662
|
|
|
|
Operating Expenses
|
|
|
General
and administrative
|
218,444
|
439,257
|
Sales
& Marketing
|
--
|
664
|
Research
and development
|
59,418
|
72,357
|
Depreciation
and amortization
|
189,652
|
426,600
|
Disposal
Loss
|
852,864
|
--
|
Impairment
loss
|
1,584,048
|
--
|
Total Operating Expenses
|
2,904,426
|
938,878
|
Operating Loss
|
(2,904,426)
|
(931,216)
|
Other Expenses
|
|
|
Interest
expense
|
9,983
|
8,040
|
Total Other Expenses
|
9,983
|
8,040
|
Net Loss
|
$(2,914,409)
|
$(939,256)
|
|
Year Ended December 31,
|
|
|
2016
|
2015
|
Cash Flows used in Operating Activities
|
$(452,592)
|
$(1,272,992)
|
Cash Flows used in Investing Activities
|
1,286
|
(1,286)
|
Cash Flows used in Financing Activities
|
--
|
(70,109)
|
Net Cash Used in Discontinued Operations
|
$(451,306)
|
$(1,344,387)
|
|
2016
|
2015
|
Statutory rate -
federal
|
34.0%
|
34.0%
|
State taxes, net of
federal benefit
|
4.0
|
4.0
|
|
|
|
Income tax
benefit
|
38.0%
|
38.0%
|
Less valuation
allowance
|
(38.0)
|
(38.0)
|
|
|
|
Total
|
0.0%
|
0.0%
|
●
|
taxable
income in prior carryback years, if carryback is permitted under
the tax law;
|
●
|
future
reversals of existing taxable temporary differences;
|
●
|
tax
planning strategies; and
|
●
|
future
taxable income exclusive of reversing temporary differences and
carryforwards.
|
|
2016
|
2015
|
Deferred
Tax Assets:
|
|
|
Start-up
costs
|
$5,738,469
|
$3,528,944
|
Share-based
compensation
|
203,761
|
57,673
|
Total
Deferred Tax Assets
|
5,942,230
|
3,586,617
|
Valuation
Allowance
|
(5,942,230)
|
(3,586,617)
|
Net
Deferred Tax Asset
|
$--
|
$--
|
Name
|
Position(s)
|
Age
|
Steve Gorlin
|
Director, Co-Chairman of the Board
|
79
|
Major General C.A. “Lou” Hennies
|
Director (2) (3)
|
79
|
James R. Andrews, M.D.
|
Director
|
75
|
Scott M. W. Haufe, M.D.
|
Director (2)
|
51
|
Ron Lawson
|
Director (1) (3)
|
72
|
Randal R. Betz, M.D.
|
Director
|
65
|
John C. Thomas, Jr.
|
Director (1)
|
63
|
Jon Mogford
|
Director
|
59
|
Larry Papasan
|
Co-Chairman of the Board (1) (2) (3)
|
76
|
Jarrett Gorlin
|
Chief Executive Officer and Director
|
41
|
Patrick Kullmann
|
President and Chief Operating Officer
|
61
|
Charles Farrahar
|
Secretary
|
56
|
Jeffery Wright
|
Chief Financial Officer
|
34
|
Dennis Moon
|
Executive Vice President
|
41
|
Manfred Sablowski
|
Senior Vice President of Sales & Marketing
|
55
|
(1)
|
Member of audit committee
|
|
|
(2)
|
Member
of compensation committee
|
|
|
(3)
|
Member
of nominating and corporate governance committee
|
|
●
|
appointing, approving the compensation of and assessing the
independence of our registered public accounting firm;
|
●
|
overseeing the work of our independent registered public accounting
firm, including through the receipt and consideration of reports
from such firm;
|
●
|
reviewing and discussing with management and the independent
registered public accounting firm our annual and quarterly
financial statements and related disclosures;
|
●
|
monitoring our internal control over financial reporting,
disclosure controls and procedures and code of business conduct and
ethics;
|
●
|
overseeing our internal audit function;
|
●
|
overseeing our risk assessment and risk management
policies;
|
●
|
establishing policies regarding hiring employees from the
independent registered public accounting firm and procedures for
the receipt and retention of accounting related complaints and
concerns;
|
●
|
meeting independently with our internal auditing staff, independent
registered public accounting firm and management;
|
●
|
reviewing and approving or ratifying any related person
transactions; and
|
●
|
preparing the audit committee report required by the Securities and
Exchange Commission, or SEC, rules.
|
●
|
identifying individuals qualified to become members of our board of
directors;
|
●
|
recommending to our board of directors the persons to be nominated
for election as directors and to each of our board’s
committees;
|
●
|
developing, recommending to the board, and assessing corporate
governance principles, codes of conduct and compliance mechanisms;
and
|
●
|
overseeing the evaluation of our board of directors.
|
●
|
reviewing and recommending corporate goals and objectives relevant
to the compensation of our chief executive officer and other
executive officers;
|
●
|
making recommendations to our board of directors with respect to,
the compensation level of our executive officers;
|
●
|
reviewing and recommending to our board of directors employment
agreements and significant arrangements or transactions with
executive officers;
|
●
|
reviewing and recommending to our board of directors with respect
to director compensation; and
|
●
|
overseeing and administering our equity-based incentive
plans;
|
●
|
personal and professional integrity, ethics and
values;
|
●
|
experience in corporate management, such as serving as an officer
or former officer of a publicly-held company;
|
●
|
development or commercialization experience in large medical
products companies;
|
●
|
experience as a board member or executive officer of another
publicly-held company;
|
●
|
strong finance experience;
|
●
|
diversity of expertise and experience in substantive matters
pertaining to our business relative to other board
members;
|
●
|
diversity of background and perspective, including with respect to
age, gender, race, place of residence and specialized
experience;
|
●
|
conflicts of interest; and
|
●
|
practical and mature business judgment.
|
Name & Position
|
|
Fiscal Year
|
|
Salary
($)
|
|
|
Bonus
($)
|
|
|
Stock Awards
($)
|
|
|
All Other Compensation ($)
|
|
|
Total
($)
|
|
|||||
Jarrett Gorlin, CEO
|
|
2015
|
|
|
272,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
272,000
|
|
|
|
2016
|
|
|
272,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
272,000
|
|
Patrick Kullmann, COO
|
|
2015
|
|
|
231,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
231,000
|
|
|
|
2016
|
|
|
231,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
231,000
|
|
Dennis Moon, EVP
|
|
2015
|
|
|
201,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
201,000
|
|
|
|
2016
|
|
|
201,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
201,000
|
|
Jeffery Wright, CFO
|
|
2015
|
|
|
130,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
130,000
|
|
|
|
2016
|
|
|
130,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
130,000
|
|
Manfred Sablowski, SVP
|
|
2015
|
|
|
150,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
150,000
|
|
|
|
2016
|
|
|
150,000
|
|
|
|
-
|
|
|
|
-
|
|
|
|
-
|
|
|
|
150,000
|
|
a.
|
Termination without cause
|
b.
|
Termination upon death or disability
|
c.
|
Termination by the Company for cause
|
d.
|
Termination by the employee for good reason, including material
diminishment of position, demands to move or change in control of
the Company
|
e.
|
Termination by the Company without cause, upon disability or by
employee with good reason
|
f.
|
Termination for other reasons
|
Name & Position
|
Annual Salary
|
Jarrett
Gorlin, CEO
|
$272,000
|
Patrick
Kullmann, President & COO
|
$231,000
|
Jeffery
Wright, CFO
|
$130,000
|
Dennis
Moon, EVP
|
$201,000
|
Manfred
Sablowski, SVP
|
$150,000
|
ITEM 12.
|
SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS
|
|
Number of Shares Beneficially Owned(1)
|
Percentage of
common equity
beneficially owned
|
Scott
M.W. Haufe, M.D., Director
|
776,610(2)(4)
|
5.1%
|
Sablowski,
Manfred, Officer
|
60,225(11)
|
0.4%
|
Jarrett
Gorlin, Director and Officer
|
560,065(3)(10)
|
3.7%
|
Larry
W. Papasan, Co-chair of the Board of Directors
|
203,576(4)
|
1.3%
|
John
C. Thomas, Jr., Director
|
85,400(4)
|
0.6%
|
Patrick
Kullmann, Officer
|
234,989(5)(8)
|
1.5%
|
Jeffery
Wright, Officer
|
29,875(7)
|
0.2%
|
Major
General C.A. “Lou” Hennies, Director
|
106,788(4)
|
0.7%
|
James
R. Andrews, M.D., Director
|
106,788(4)
|
0.7%
|
Ron
Lawson, Director
|
150,000(12)
|
1.0%
|
Steve
Gorlin, Co-chair of the Board of Directors
|
1,195,789(6)
|
7.8%
|
Randal
R. Betz, M.D., Director
|
106,788(4)
|
0.7%
|
Mogford
Jon, Director
|
75,000(13)
|
0.5%
|
Dennis
Moon, Officer
|
208,614(9)
|
1.4%
|
Officers and Directors as a Group (14 persons)
|
3,900,507
|
25.6%
|
(1)
|
Beneficial ownership is determined in accordance with the rules of
the Securities and Exchange Commission and includes voting or
investment power with respect to shares beneficially owned and
options exercisable within 60 days. Beneficial ownership is based
on information furnished by the individuals or
entities.
|
(2)
|
Includes 532,335 shares held by Morgan Stanley Smith Barney
custodian for Nicole Haufe Roth IRA, 25,000 shares held by Haufe
Family Limited Partnership and 209,275 shares held by Nicole Haufe.
Mr. Haufe disclaims beneficial ownership of the
shares.
|
(3)
|
Includes 506,837 shares held by The Jarrett S. & Rebecca L.
Gorlin Family Limited Partnership. Mr. Gorlin disclaims beneficial
ownership of the shares.
|
(4)
|
Includes 10,000 shares pursuant to options exercisable within 60
days.
|
(5)
|
Includes 96,788 shares held by Pamela M.C. Kullmann. Mr. Kullmann
disclaims beneficial ownership of Pamela M.C. Kullmann’s
shares.
|
(6)
|
Includes 125,000 shares held by Mr. Gorlin's spouse, Deborah
Gorlin. Mr. Gorlin disclaims beneficial ownership of Deborah
Gorlin’s shares.
|
(7)
|
Includes 29,875 shares pursuant to options exercisable within 60
days.
|
(8)
|
Includes 26,163 shares pursuant to options exercisable within 60
days.
|
(9)
|
Includes 15,038 shares pursuant to options exercisable within 60
days.
|
(10)
|
Includes 10,200 shares pursuant to options exercisable within 60
days.
|
(11)
|
Includes 55,625 shares pursuant to options exercisable within 60
days.
|
(12)
|
Includes 150,000 shares pursuant to options exercisable within 60
days.
|
(13)
|
Includes 75,000 shares pursuant to options exercisable within 60
days.
|
●
|
qualified incentive stock options
(“QISOs”);
|
●
|
nonqualified stock options; and
|
●
|
awards of restricted stock and/or restricted stock
units.
|
ITEM 13.
|
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
|
●
|
the related person’s interest in the related person
transaction;
|
●
|
the approximate dollar value of the amount involved in the related
person transaction;
|
●
|
the
approximate dollar value of the amount of the related
person’s interest in the transaction
without regard to the amount of any profit or
loss;
|
●
|
whether the transaction was undertaken in the ordinary course of
our business;
|
●
|
whether the terms of the transaction are no less favorable to us
than terms that could have been reached with an unrelated
third party; and
|
●
|
the purpose of, and the potential benefits to us of, the
transaction.
|
●
|
interests arising solely from the related person’s position
as an executive officer of another entity (whether or not the
person is also a director of such entity) that is a participant in
the transaction, where (i) the related person and all other
related persons own in the aggregate less than a 10% equity
interest in such entity, (ii) the related person and his or her
immediate family members are not involved in the negotiation of the
terms of the transaction and do not receive any special benefits as
a result of the transaction and (iii) the amount involved in the
transaction is less than the greater of $200,000 or 5% of the
annual gross revenues of the company receiving payment under the
transaction; and
|
●
|
a transaction that is specifically contemplated by provisions of
our charter or bylaws.
|
|
Fiscal Year
2016
|
Fiscal Year
2015
|
Audit
fees
|
$108,500
|
125,155
|
Tax
fees – Frazier & Deeter
|
16,000
|
$12,500
|
Total
|
$124,500
|
$137,655
|
|
|
F-2
|
|
F-3
|
|
F-4
|
|
F-5
|
|
F-6
|
|
F-7
|
|
|
MEDOVEX CORP.
|
Date: March 31,
2017
|
By:
|
/s/ Jarrett Gorlin
Jarrett Gorlin,
Chief Executive Officer
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/ Jarrett Gorlin
|
|
Chief Executive Officer, President and Director
|
|
|
Jarrett Gorlin
|
|
(Principal Executive Officer)
|
|
March 31, 2017
|
|
|
|
|
|
/s/ Jeffery Wright
|
|
Chief Financial Officer
|
|
|
Jeffery Wright
|
|
(Principal Financial and Accounting Officer)
|
|
March 31, 2017
|
|
|
|
|
|
/s/ Larry Papasan
|
|
|
|
|
Larry Papasan
|
|
Chairman of the Board of Directors
|
|
March 31, 2017
|
|
|
|
|
|
/s/ Clyde A. Hennies
|
|
|
|
|
Clyde A. Hennies
|
|
Director
|
|
March 31, 2017
|
|
|
|
|
|
/s/ Scott M.W. Haufe
|
|
|
|
|
Scott M.W. Haufe
|
|
Director
|
|
March 31, 2017
|
|
|
|
|
|
/s/ James R. Andrews
|
|
|
|
|
James R. Andrews
|
|
Director
|
|
March 31, 2017
|
|
|
|
|
|
/s/ Ron Lawson
|
|
|
|
|
Ron Lawson
|
|
Director
|
|
March 31, 2017
|
|
|
|
|
|
/s/ Randal R. Betz
|
|
|
|
|
Randal R. Betz
|
|
Director
|
|
March 31, 2017
|
|
|
|
|
|
/s/ Steve Gorlin
|
|
|
|
|
Steve Gorlin
|
|
Director
|
|
March 31, 2017
|
|
|
|
|
|
/s/ John Thomas
|
|
|
|
|
John Thomas
|
|
Director
|
|
March 31, 2017
|
/s/ Jon Mogford
|
|
|
|
|
Jon Mogford
|
|
Director
|
|
March 31, 2017
|
Exhibit Number
|
|
Description
|
2.1
|
|
Agreement and Plan of Merger, dated September 16, among MedoveX
Corp. f/k/a SpineZ Corp. and Debride Inc. (1)
|
2.2
|
|
Agreement and Plan of Merger, dated March 9, 2015 among MedoveX
Corp. and Streamline, Inc. (2)
|
2.3
|
|
Asset Purchase Agreement dated December 7, 2016 among MedoveX
Corp., Streamline, Inc., Skytron, LLC and certain other parties
thereto (3)
|
3.1
|
|
Articles of Incorporation of Spinez Corp. (1)
|
3.2
|
|
Certificate of Amendment to the Articles of Incorporation of Spinez
Corp. (changing the name of the company to MedoveX Corp. and
Effecting the Reverse Split of the Outstanding Shares of MedoveX
Corp.’s Common Stock).
|
3.3
|
|
Bylaws of MedoveX Corp. (1)
|
3.4
|
|
Certificate of Designation for Series A Preferred Stock
(4)
|
4.1
|
|
Modification
Agreement by and between the Company and Steve Gorlin dated January
25, 2016. (5)
|
4.2
|
|
Amendment
to the Modification Agreement by and between the Company and Steve
Gorlin dated February 16, 2016. (6)
|
4.3
|
|
Second
Amendment to the Modification Agreement by and between the Company
and Steve Gorlin dated March 25, 2016. (7)
|
4.4
|
|
Third
Amendment to the Modification Agreement by and between the Company
and Steve Gorlin dated November 1, 2016. (7)
|
4.5
|
|
Fourth
Amendment to the Modification Agreement by and between the Company
and Steve Gorlin dated November 30, 2016. (8)
|
10.1
|
|
2013 Stock Incentive Plan. (1)
|
10.2
|
|
Employment Agreement between MedoveX Corp. and Jarrett Gorlin dated
October 14, 2013. (1)
|
10.3
|
|
Employment Agreement between MedoveX Corp. and Patrick Kullmann
dated October 14, 2013. (1)
|
10.4
|
|
Employment Agreement between MedoveX Corp. and Charlie Farrahar
dated October 14, 2013. (1)
|
10.5
|
|
Employment Agreement between MedoveX Corp. and Dennis Moon dated
November 11, 2013. (1)
|
10.6
|
|
Contribution and Royalty Agreement between MedoveX and Scott W.
Haufe dated January 31, 2013. (1)
|
10.7
|
|
Co-Development Agreement between MedoveX Corp. and Dr. James
Andrews dated September 30, 2013. (1)
|
10.8
|
|
Consulting Agreement between MedoveX Corp. and Robb Knie dated
December 2, 2013. (1)
|
10.9
|
|
Engineering Services Agreement between MedoveX Corp. and Devicix,
LLC dated November 25, 2013. (1)
|
10.10
|
|
Form of Indemnification Agreement. (1)
|
10.11
|
|
Promissory
note issued on November 9, 2015 in favor of Steve
Gorlin
|
10.12
|
|
Warrant
issued on November 9, 2015 to Steve Gorlin
|
10.13
|
|
Form of
Common Stock Purchase Warrant (9)
|
10.14
|
|
Form of Unit Purchase Agreement between MedoveX Corp. and Investors
(10)
|
10.15
|
|
Form of Registration Rights Agreement between MedoveX Corp. and
Investors (10)
|
10.16
|
|
Private Placement Memorandum Supplement dated April 18, 2016
(10)
|
10.17
|
|
Form of Warrant (11)
|
10.18
|
|
Form of Unit Purchase Agreement (11)
|
10.19
|
|
Form of Registration Rights Agreement (11)
|
10.20
|
|
Form of Note (12)
|
10.21
|
|
Form of Warrant (12)
|
10.22
|
|
Form of Security Agreement (12)
|
10.23
|
|
Form of Warrant (4)
|
10.24
|
|
Form of Unit Purchase Agreement (4)
|
10.25
|
|
Form of Registration Rights Agreement (4)
|
14
|
|
Business and Code of Ethics of MedoveX Corp. (1)
|
21.1
|
|
Subsidiaries of MedoveX Corp. *
|
24.1
|
|
Power of Attorney (included on signature page).*
|
31.1
|
|
Certification of Chief Executive Officer pursuant to Section 302 of
the Sarbanes-Oxley Act of 2002.*
|
31.2
|
|
Certification of Principal Financial and Accounting Officer
pursuant to Section 302 of the Sarbanes-Oxley Act of
2002.*
|
32.1
|
|
Certification of Chief Executive Officer pursuant to Section 906 of
the Sarbanes-Oxley Act of 2002.*
|
32.2
|
|
Certification of Principal Financial and Accounting Officer
pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.*
|
(1)
|
Incorporated by reference herein from the Registration Statement on
Form S-1/A filed on December 9, 2014.
|
(2)
|
Incorporated by reference herein from the Current Report on Form
8-K filed on March 11, 2015.
|
(3)
|
Incorporated by reference herein from the Current Report on Form
8-K filed on December 12, 2016
|
(4)
|
Incorporated by reference herein from the Current Report on From
8-K filed on February 14, 2017
|
(5)
|
Incorporated by reference herein from the Current Report on Form
8-K filed on January 25, 2016.
|
(6)
|
Incorporated by reference herein from the Current Report on Form
8-K filed on February 17, 2016.
|
(7)
|
Incorporated by reference herein from the Current Report on Form
8-K filed on November 4, 2016
|
(8)
|
Incorporated by reference herein from the Current Report on Form
8-K filed on December 6, 2016
|
(9)
|
Incorporated by reference herein from the Current Report on Form
8-K filed on April 25, 2016.
|
(10)
|
Incorporated by reference herein from the Current Report on Form
8-K filed on May 5, 2016.
|
(11)
|
Incorporated by reference herein from the Current Report on Form
8-K filed on August 8, 2016
|
(12)
|
Incorporated by reference herein from the Current Report on Form
8-K filed on September 19, 2016
|
(*)
|
Filed herewith
|
Name of Entity
|
|
Jurisdiction
|
Debrider,
Inc.
|
|
Florida
|
STML
Merger Sub, Inc.
|
|
Minnesota
|
1.
|
I have reviewed this Annual Report on Form 10-K of MedoveX
Corp.;
|
2.
|
Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in
all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the
periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are
responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
|
|
(a)
|
Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the
period in which this report is being prepared;
|
|
(b)
|
Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;
|
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure
controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report
based on such evaluation; and
|
|
(d)
|
Disclosed in this report any change in the registrant’s
internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over
financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and
the audit committee of the registrant’s board of directors
(or persons performing the equivalent functions):
|
|
(a)
|
All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial
information; and
|
|
(b)
|
Any fraud, whether or not material, that involves management or
other employees who have a significant role in the
registrant’s internal control over financial
reporting.
|
/s/ Jarrett Gorlin
|
|
Jarrett Gorlin,
Principal Executive Officer
|
|
1.
|
I have reviewed this Annual Report on Form 10-K of MedoveX
Corp.;
|
2.
|
Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the
circumstances under which such statements were made, not misleading
with respect to the period covered by this report;
|
3.
|
Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in
all material respects the financial condition, results of
operations and cash flows of the registrant as of, and for, the
periods presented in this report;
|
4.
|
The registrant’s other certifying officer and I are
responsible for establishing and maintaining disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the
registrant and have:
|
|
(a)
|
Designed such disclosure controls and procedures, or caused such
disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the
registrant, including its consolidated subsidiaries, is made known
to us by others within those entities, particularly during the
period in which this report is being prepared;
|
|
(b)
|
Designed such internal control over financial reporting, or caused
such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally
accepted accounting principles;
|
|
(c)
|
Evaluated the effectiveness of the registrant’s disclosure
controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and
procedures, as of the end of the period covered by this report
based on such evaluation; and
|
|
(d)
|
Disclosed in this report any change in the registrant’s
internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of an annual
report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over
financial reporting; and
|
5.
|
The registrant’s other certifying officer and I have
disclosed, based on our most recent evaluation of internal control
over financial reporting, to the registrant’s auditors and
the audit committee of the registrant’s board of directors
(or persons performing the equivalent functions):
|
|
(a)
|
All significant deficiencies and material weaknesses in the design
or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial
information; and
|
|
(b)
|
Any fraud, whether or not material, that involves management or
other employees who have a significant role in the
registrant’s internal control over financial
reporting.
|
/s/ Jeffery Wright
|
|
Jeffery Wright,
Principal Financial and Accounting Officer
|
|
Date: March 31,
2017
|
|
||
|
|
|
|
By:
|
|
/s/ Jarrett Gorlin
|
|
Name:
|
|
Jarrett Gorlin
|
|
Title:
|
|
Principal Executive Officer
|
|
Date: March 31,
2017
|
|
||
|
|
|
|
By:
|
|
/s/ Jeffery Wright
|
|
Name:
|
|
Jeffery Wright
|
|
Title:
|
|
Principal Financial and Accounting Officer
|
|
Document and Entity Information - USD ($) |
12 Months Ended | ||
---|---|---|---|
Dec. 31, 2016 |
Mar. 28, 2017 |
Jun. 30, 2016 |
|
Document And Entity Information | |||
Entity Registrant Name | MEDOVEX CORP. | ||
Entity Central Index Key | 0001591165 | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2016 | ||
Amendment Flag | false | ||
Current Fiscal Year End Date | --12-31 | ||
Is Entity a Well-known Seasoned Issuer? | No | ||
Is Entity a Voluntary Filer? | Yes | ||
Is Entity's Reporting Status Current? | Yes | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Common Stock, Shares Outstanding | 17,026,688 | ||
Entity Public Float | $ 17,816,836 | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2016 |
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares |
Dec. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Stockholders' Equity | ||
Preferred stock, par value | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized | 500,000 | 500,000 |
Preferred stock, shares outstanding | 0 | 0 |
Common stock, par value | $ .001 | $ .001 |
Common stock, shares authorized | 49,500,000 | 49,500,000 |
Common stock, shares issued | 14,855,181 | 11,256,175 |
Common stock, shares outstanding | 14,855,181 | 11,048,203 |
ORGANIZATION |
12 Months Ended |
---|---|
Dec. 31, 2016 | |
Notes to Financial Statements | |
ORGANIZATION | Description of Business
MedoveX Corp. (the “Company” or “MedoveX”), was incorporated in Nevada on July 30, 2013 as SpineZ Corp. (“SpineZ”) and changed its name to MedoveX Corp. on March 20, 2014. MedoveX is the parent company of Debride Inc. (“Debride”), which was incorporated under the laws of the State of Florida on October 1, 2012. The Company is in the business of designing and marketing proprietary medical devices for commercial use in the United States and Europe. The Company is currently seeking approval from the FDA and CE for DenerveX device.
In March 2015, the Board of Directors of MedoveX and Streamline, Inc., a Minnesota corporation (“Streamline”), approved an Agreement and Plan of Merger (the “Merger Agreement”). Under the Merger Agreement, STML Merger Sub, Inc. a wholly-owned subsidiary of MedoveX, merged into Streamline, after which Streamline became a wholly-owned subsidiary of Medovex.
In May 2016, the Board of Directors authorized management to seek buyers for Streamline, Inc., the Company’s wholly owned subsidiary acquired in March 2015. In December 2016, the Company entered into a definitive asset purchase agreement pursuant to which the Company agreed to sell all Streamline assets upon consummation of the divestiture (the “Closing”). The Closing occurred immediately following the execution of the asset purchase agreement on December 7, 2016. (See Note 10)
|
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
12 Months Ended |
---|---|
Dec. 31, 2016 | |
Notes to Financial Statements | |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES | BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION
The accompanying financial statements include the accounts of Medovex Corp. and its wholly-owned subsidiary, Streamline. All intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates
In preparing the financial statements, generally accepted accounting principles in the United States (“U.S. GAAP”) requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. Actual results could differ from those estimates.
Concentration of Credit Risk
Financial instruments, which potentially subject the Company to concentrations of credit risk, consist solely of cash. At times throughout the year, the Company may maintain certain bank account balances in excess of FDIC insured limits. At December 31, 2016 and 2015, the Company had cash deposits that exceeded federally insured deposit limits. The Company believes that its funds are deposited in high credit quality financial institutions. The Company has not experienced any losses in such accounts to date and believes it is not exposed to any significant credit risk associated with its cash deposits.
Cash
The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash balances at December 31, 2016 and 2015 consists of funds deposited in checking accounts with commercial banks.
Long term Receivable
The long term receivable at December 31, 2016 represents the long-term, non-contingent portion of the receivables due from the sale of Streamline which is not due until January 1, 2018. See Note 10. Recording the present value of the receivable at December 31, 2016 and recognizing the subsequent accretion expense over the one year period led to an immaterial amount.
Goodwill And Purchased Intangible Assets
Goodwill is reviewed for impairment annually on December 31 or more frequently if changes in circumstances or the occurrence of events suggest impairment exists using a two-step process. In step 1, the fair value of each reporting unit is compared to its carrying value, including goodwill. If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and the Company would then complete step 2 in order to measure the impairment loss. In step 2, the Company would calculate the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets (including unrecognized intangible assets) of the reporting unit from the fair value of the reporting unit. If the implied fair value of goodwill is less than the carrying value of goodwill, the Company would recognize an impairment loss, in the period identified, equal to the difference. See Note 11.
Other intangible assets consist of developed technology and a trademark. The Company reviews intangible assets for impairment as changes in circumstances or the occurrence of events suggest the remaining value may not be recoverable. See Note 11.
Amortization on the intangibles was provided on a straight-line basis over the estimated useful lives of the assets as follows:
Trademark 5 years Developed technology 7 years
Although we believe that the recorded fair value of our non-financial assets is appropriate at December 31, 2016, these fair values may not be indicative of net realizable value or reflective of future fair values.
Fair Value Measurements
We measure certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations.
We use the fair value measurement framework to value these assets and report the fair values in the periods in which they are recorded or written down.
The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows:
• Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;
• Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and
• Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.
The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. We may also engage external advisors to assist us in determining fair value, as appropriate.
Although we believe that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.
Property and Equipment
Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to five years. Repairs and maintenance are expensed as incurred. Improvements and betterments, which extend the lives of the assets, are capitalized.
Leases
The Company recognizes rent expense on a straight-line basis over the term of the lease. The lease term commences on the date the Company takes possession of or controls the physical use of the property. Deferred rent is included in non-current liabilities on the balance sheet.
Research and Development
Research and development costs are expensed as incurred.
Advertising
The Company expenses all advertising costs as incurred. For the years ended December 31, 2016 and 2015, advertising costs were approximately $392,000 and $102,000, respectively.
Income Taxes
The Company uses the liability method of accounting for income taxes, which requires recognition of temporary differences between financial statement and income tax bases of assets and liabilities, measured by enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets when necessary.
Stock-Based Compensation
The Company maintains a stock option incentive plan and accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation. The Company recognizes share-based compensation expense, net of an estimated forfeiture rate, over the requisite service period of the award to employees and directors. As required by fair value provisions of share-based compensation, employee and non-employee share-based compensation expense recognized is calculated over the requisite service period of the awards and reduced for estimated forfeitures.
Loss per Share
Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti- dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share: 3,504,847 warrants and 1,124,900 common stock options outstanding were considered anti-dilutive and excluded for the years presented.
Business combinations
The Company completed an acquisition on March 25, 2015. This transaction was recorded using guidelines provided by ASC 805, Business Combinations. Following these guidelines, the consideration paid by MedoveX for Streamline was measured on the date of acquisition. An independent valuation of Streamline was performed using the discounted cash flow method. Based on the estimated value of Streamline, the consideration paid by MedoveX and the tangible assets of Streamline, management determined the intangible portion of the purchase price should be assigned between developed technology, trademark, and goodwill.
Discontinued Operations
As more fully described in Note 10, in May 2016, management was authorized to locate a buyer for Streamline Inc., the Company’s wholly owned subsidiary acquired in March 2015, by the Board of Directors. Streamline’s results of operations have been classified as discontinued operations for all periods presented.
reclassification
Some items in the prior period financial statements were reclassified to conform to the current period presentation. Reclassifications had no effect on prior period net income or shareholders’ equity.
Recently Issued Accounting Pronouncements In August 2014, FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, or ASU 2014-15. ASU 2014-15 explicitly requires a company’s management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The new standard will be effective in the first annual period ending after December 15, 2016, although early application is permitted. We do not expect the adoption of this standard to have a material impact on our consolidated statements of financial position, results of operations or cash flows.
In April 2015, FASB issued ASU No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the presentation of Debt Issuance Costs, to reduce the complexity of having different balance sheet presentation requirements for debt issuance costs and debt discounts and premiums. The guidance requires debt issuance costs related to a recognized debt liability be reported on the balance sheet as a direct deduction from the carrying amount of that debt liability. ASU 2015-03 is effective for public companies for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. The Company has adopted the amendments of ASU 2015-03 effective January 1, 2016.
In November 2015, FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. We believe the adoption of this standard will have no material impact on our consolidated statements of financial position, results of operations or cash flows.
In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.
|
PROPERTY AND EQUIPMENT |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
PROPERTY AND EQUIPMENT | Property and equipment consists of the following:
Depreciation and amortization expense, excluding depreciation and amortization from Streamline, Inc., amounted to $11,267 for the year ended December 31, 2016 and $6,498 for the year ended December 31, 2015.
|
PATENT ASSIGNMENT AND CONTRIBUTION AND AGREEMENTS |
12 Months Ended |
---|---|
Dec. 31, 2016 | |
Notes to Financial Statements | |
PATENT ASSIGNMENT AND CONTRIBUTION AND AGREEMENTS | On February 1, 2013, the Company issued 750,108 shares of common stock to Scott Haufe, M.D. (“Dr. Haufe”) pursuant to the terms of a Contribution and Royalty Agreement dated January 31, 2013 between the Company and Dr. Haufe. This agreement provides for the Company to pay Dr. Haufe royalties equal to 1% of revenues earned from sales of any and all products derived from the use of the DenerveX technology. Royalties are payable to Dr. Haufe within 30 days after the close of each calendar quarter based on actual cash collected from sales of applicable products. The royalty period expires on September 6, 2030. No royalties have been paid as of December 31, 2016.
The Company executed a co-development agreement for the DenerveX technology with royalty provisions with James R. Andrews, M.D., as more fully described in Note 7. |
ACQUISITIONS |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ACQUISITIONS | On March 25, 2015, the Company acquired Streamline Inc. pursuant to an Agreement and Plan of Merger dated March 9, 2015. As a result of this transaction, Streamline, Inc. became a wholly owned subsidiary of the Company. Under the terms of the Agreement and Plan of Merger, the Company paid $1,397,466 cash and authorized the issuance of 1,875,000 shares of common stock, of which 200,000 shares were held in escrow until September 25, 2016 to satisfy indemnification obligations under the agreement. The Company incurred approximately $344,000 in acquisition related legal fees.
On September 25, 2016, the escrow was released for the full 200,000 shares. As of December 31, 2016, the Company had received transmittal letters for all of the 1,875,000 shares of MedoveX common stock. The terms of the Merger Agreement also required a commitment by MedoveX to supply a minimum of $750,000 in working capital to the Streamline subsidiary, to fund the operations and product development of Streamline as needed. The $750,000 working capital funding commitment was fully satisfied upon consummation of the divestiture. See Note 10.
The closing price of the common stock on March 25, 2015 was $4.50 per share. Based on this price and cash consideration, the acquisition of Streamline was valued at $9,834,966.
The following is a summary of the allocation of the fair value of Streamline.
|
EQUITY TRANSACTIONS |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes to Financial Statements | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EQUITY TRANSACTIONS | Private Placements
In April 2016, the Company entered into a unit purchase agreement with selected accredited investors whereby the Company had the right to sell in a private placement a minimum of $1,000,000 and up to a maximum of $2,000,000 of units. Each unit had a purchase price of $100,000 and consisted of (i) 86,957 shares of the Company’s common stock, par value $0.001 per share at a purchase price of $1.15 per share, and (ii) a warrant to purchase 43,478 shares of common stock. Each warrant has an exercise price of $1.30 per share and is exercisable six months following the date of issuance for a period of five (5) years from the date of issuance.
The offering resulted in gross proceeds of $1,398,034 and resulted in the issuance of an aggregate of 1,211,703 shares of common stock and warrants to purchase 605,829 shares. The Placement Agent collected an aggregate of approximately $222,000 in total fees related to the offering and was also issued warrants on the same terms to purchase an aggregate of 181,992 shares.
On August 5, 2016, the Company entered into a Unit Purchase Agreement with selected accredited investors whereby the Company had the right to sell in a private placement a minimum of $250,000 and up to a maximum of $1,300,000 of units. Each Unit had a purchase price of $250,000 and consisted of (i) 208,333 shares of the Company’s common stock, par value $0.001 per share at a purchase price of $1.20 per share, and (ii) a warrant to purchase 104,167 shares of Common Stock. Each Warrant has an initial exercise price of $1.52 per share, and is initially exercisable six months following the date of issuance for a period of five (5) years from the date of issuance.
The offering resulted in gross proceeds of $1,300,000 and resulted in the issuance of an aggregate of 1,083,333 shares of common stock and warrants to purchase 541,669 shares.
Stock-Based Compensation
During 2016, we issued 180,500 shares of common stock under consulting agreements for investor relation services. These shares were valued based upon the closing price of our stock at the respective dates, ranging from $1.28 to $1.50 per share and valued at $249,300. Additionally, in conjunction with the share based payments, we also paid $535,000 under the consulting agreements for the investor relations services.
On November 10, 2016, the Board authorized the issuance of shares of common stock, priced at the average closing price of the Company’s stock during 2016, to all Board members, both current and former, in an amount equivalent to $240,000, representing their accrued but unpaid directors’ fees as of December 31, 2016. In January 2017, the Company issued 173,911 shares at $1.38 per share to fulfill this obligation.
Stock-Based Compensation Plan
2013 Stock Option Incentive Plan
On October 14, 2013, shareholders approved the MedoveX Corp. 2013 Stock Incentive Plan (the “Plan”). Under the Plan, the Company may grant incentive stock options to employees and non-statutory stock options to employees, consultants, and directors for up to 1,150,000 shares of common stock. On November 10, 2016, shareholders approved a 500,000 share increase in the number of shares available for issuance under the Plan, from 1,150,000 to 1,650,000 shares.
The stock options are exercisable at a price equal to the market value on the date of the grant. The Plan gives full authority for granting options, determining the type of options granted, and determining the fair market value of the options to the Plan Administrator.
The Company has the right, but not obligation, to repurchase any shares obtained through exercise of an option from terminated Plan participants. The Company has 90 days from the date of termination to exercise it’s repurchase right. The Company must pay the Fair Market Value (“FMV”) of the shares if the termination was for any reason other than for cause, or the option price (if less than FMV of the shares) if the termination is for cause. The FMV is determined by the Plan Administrator on the date of termination.
During 2016, the Company granted options to purchase 294,900 shares of common stock to certain employees and consultants. 274,900 of the options vest as follows: 25% on the date of grant and 25% on each of the next three anniversaries. The options granted were at the market value of the common stock on the date of the grant. The remaining 20,000 options vest as follows: 50% on the date of grant and 50% one year after the grant date and are exercisable at $1.20. The market value of these remaining common stock on the date of grant was $1.28.
During 2016, the Company granted options to purchase 450,000 shares of common stock to certain directors that vest as follows: 50% on the date of grant and 50% one year after the grant date. 300,000 of the options are exercisable at $1.20. The market value of these common stock on the date of grant was $1.28. The remaining 150,000 options are exercisable at $1.58 which was the fair value of the common stock on the grant date.
We utilize the Black-Scholes valuation method to recognize compensation expense over the vesting period. The expected life represents the period that our stock-based compensation awards are expected to be outstanding.
We use a simplified method provided in Securities and Exchange Commission release, Staff Accounting Bulletin No. 110, which averages an award's weighted average vesting period and contractual term for "plain vanilla" share options. The expected volatility was estimated by analyzing the historic volatility of similar public biotech companies in an early stage of development.
No dividend payouts were assumed as we have not historically paid, and do not anticipate paying, dividends in the foreseeable future. The risk-free rate of return reflects the weighted average interest rate offered for US treasury rates over the expected term of the options.
For the years ended December 31, 2016 and 2015, the Company recognized approximately $777,000 and $254,000, respectively, as compensation expense with respect to stock options.
A summary of the Company’s share-based compensation activity and related information is as follows:
As of December 31, 2016, there were 601,175 shares of time-based, non-vested stock. Unrecognized compensation cost amounts to approximately $596,000 as of December 31, 2016 and will be recognized as an expense on a straight-line basis over a remaining weighted average service period of 1.7 years. The fair value of vested share-based compensation at December 31, 2016 and 2015 was approximately 697,000 and $138,000, respectively.
|
COMMITMENTS |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||
Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||
COMMITMENTS | Operating Leases
Office Space
The Company pays TAG Aviation, a company owned by its Chief Executive Officer, Jarrett Gorlin (“Mr. Gorlin”) for office space that is currently being used as the Company’s principal business location plus utilities (see “Related Party Transactions”) on a monthly basis. Payments under this arrangement are $2,147 per month. Rent expense and utilities cost paid to TAG Aviation amounted to approximately $30,400 and $28,400 for the years ended December 31, 2016 and 2015, respectively.
On July 8, 2015, the Company entered into a 3 year lease agreement for a commercial building which commenced on August 1, 2015. Total lease expense for the year ended December 31, 2016 and 2015 was approximately $34,000 and $14,000, respectively, related to this lease. Future minimum lease payments under this rental agreement are approximately as follows:
For the year ended:
Equipment
The Company entered into a non-cancelable 36 month operating lease agreement for equipment on April 22, 2015. The agreement is renewable at the end of the term and requires the Company to maintain comprehensive liability insurance.
Total lease expense for the year ended December 31, 2016 was approximately $2,600. Future minimum lease payments under this operating lease agreement are approximately as follows:
For the year ended:
Purchase Orders
For the years ended December 31, 2016 and 2015, the Company had approximately $234,000 and $484,000, respectively, in outstanding purchase order obligations related to the research and development build of the DenerveX device to Nortech and Bovie Medical Corporation (“Bovie”).
Consulting Agreements
The Company has a consulting agreement with one its’ founding stockholders to provide business development consulting services through January 2017 at a fee of $5,000 per month. The agreement was subsequently extended and increased to $10,000 per month through January 18, 2018. See Note 16.
The Company has a consulting agreement with a sales consultant to provide sales, marketing and distribution consulting services over a one-year period for €10,000 per month through August 1, 2017.
As described in Note 6, on September 15, 2016, the Company entered into a six month business advisory and investor relations consulting agreement at a fee of $400,000 for the purpose of creating market awareness of the Company.
Employment Agreements
The Company entered into Employment Agreements with each of its five executive officers for aggregate compensation amounting to approximately $984,000 per annum, plus customary benefits. These employment agreements, having commenced at separate dates, are for terms of three years which began in October 2013 and ends in January 2018.
The agreements provide for the Company to pay six months of severance in the event of (i) the Company’s termination of an executive’s employment without cause, (ii) the resignation by an executive for good reason, (iii) a change in control of the Company, (iv) a material reduction in an executive’s duties, or (v) a requirement that an executive move their primary work location more than 50 miles.
Co-Development Agreement
In September 2013, the Company executed a Co-Development Agreement with James R. Andrews, M.D. (“Dr. Andrews”) to further evaluate, test and advise on the development of products incorporating the use of the patented technology. In exchange for these services the Company is obligated to pay Dr. Andrews a royalty of 2% of revenues earned from applicable product sales over a period of 5 years. If Dr. Andrews is listed as inventor of any Improvement Patent on the DenerveX device during the 5 year term, he would continue to receive a 1% royalty after the 2% royalty expires for the duration of the effectiveness of the Improvement Patent. No royalties have been paid to Dr. Andrews as of December 31, 2016.
Generator development agreement
The Company is obligated to reimburse Bovie up to $295,000 for the development of the Pro-40 electrocautery generator. For the year ended December 31, 2016 and 2015, the Company paid approximately $102,400 and $181,200, respectively, under this agreement.
|
SHORT TERM LIABILITIES |
12 Months Ended | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||
Debt Disclosure [Abstract] | |||||||||||||
SHORT TERM LIABILITIES | Finance Agreement
The Company entered into a commercial insurance premium finance and security agreement in December 2016. The agreement finances the Company’s annual D&O insurance premium. Payments are due in quarterly installments of approximately $23,000 and carry an annual percentage interest rate of 4.9%.
The Company had an outstanding premium balance of approximately $65,000 at December 31, 2016 related to the agreement.
Promissory Notes
In conjunction with the consummation of the Streamline acquisition on March 25, 2015, the Company assumed two promissory notes for approximately $135,000 and $125,000 payable to the Bank of North Dakota New Venture Capital Program and North Dakota Development Fund, both outside non-related parties. Assumption of the liabilities was not included as part of the asset purchase agreement that was executed in December 2016. Thus, the Company retained the promissory notes upon consummation of the divestiture.
Payments on both of the notes are due in aggregate monthly installments of approximately $5,700 and carry an interest rate of 5%. Both of the notes have a maturity date of August 1, 2019. The promissory notes had outstanding balances of approximately $165,000 and $223,000 at December 31, 2016 and December 31, 2015, respectively.
Expected future payments related to the promissory notes as of December 31, 2016, are approximately as follows:
For the year ended:
The Company paid interest expense related to the promissory notes for the year ended December 31, 2016 and 2015 in the amount of approximately $10,000 and $8,000, respectively. The Company had unpaid accrued interest in the amount of approximately $69,000 at December 31, 2016 and 2015 related to the promissory notes.
Convertible Debt
On November 9, 2015, the Company issued a convertible promissory note, (the “Convertible Note”) to Steve Gorlin, a director and the father of Jarrett Gorlin, the Company’s CEO, for the principal amount of up to $2,000,000. The loan principal was to be advanced in two installments of $1,000,000 each, the first installment being made upon execution of the promissory note and the second installment to be made by March 1, 2016.
The Convertible Note provided that the principal and accrued but unpaid interest could be converted into common stock at $2 per share. The outstanding principal was to earn interest at a rate of 5.5% per annum and was to be paid quarterly. The Company also issued a 3 year warrant to Mr. Steve Gorlin to purchase 500,000 shares of common stock at $2.20 per share (see Note 9).
On January 25, 2016, the Company entered into a modification agreement (the “Modification Agreement”) with Mr. Steve Gorlin. Mr. Gorlin agreed to immediately convert the promissory note into an aggregate of 571,429 shares of its Common Stock, eliminating the Company’s $1,000,000 debt obligation and any accrued interest in exchange for amending the conversion price of the promissory note from $2.00 per share to $1.75 per share.
Additionally, Mr. Gorlin also agreed to acquire 571,429 additional shares of Common Stock at a price of $1.75 per share for a total purchase price of $1,000,000 within two months from the date of the agreement. The January 25, 2016 modification agreement also amended the exercise price of the warrant issued to Mr. Gorlin on November 9, 2015 from $2.20 per share to $2.00 per share (see note 9).
On February 16, 2016, the Company and Steve Gorlin entered into an Amendment to the Modification Agreement in order to reduce the amount of shares of Common Stock that Mr. Gorlin was to receive upon the conversion of the $1,000,000 promissory note from 571,429 ($1.75 per share) shares to 552,041 ($1.81 per share) shares. In consideration for reducing the amount of shares of common stock that he was to receive, the Company agreed to reduce the exercise price of Steven Gorlin’s 500,000 share warrant from $2.00 per share to $1.825 per share (see Note 9).
On March 15, 2016, the Board of Directors approved a second amendment to the Modification Agreement. The date for making the second installment of $1,000,000 was extended to November 1, 2016.
Additionally, the language in the Note was changed to clarify that the consideration received by the Company on the first installment was in the form of $970,000 cash and $30,000 in directors’ fees due to Mr. Steve Gorlin. The $30,000 in directors’ fees was recorded as a reduction in equity and is expensed as earned. $10,000 of directors fees were earned in 2015 after issuance of the note. For the year ended December 31, 2016, the remaining $20,000 of directors’ fees were earned by Mr. Gorlin so there was no outstanding balance at December 31, 2016.
On November 10, 2016, the Board of Directors approved a third amendment to the Modification Agreement. The date for making the second installment of $1,000,000 was extended to December 1, 2016.
On December 1, 2016, the Board of Directors approved a fourth amendment to the Modification Agreement. Pursuant to the fourth amendment, Mr. Gorlin assigned a portion of the obligation to purchase the additional 571,429 shares of the Company at $1.75 per share.
The obligation to purchase 142,857 of the additional shares was assigned to an outside non-related party for a total purchase price of $250,000.
Additionally, the obligation to purchase 114,286 of the additional shares was assigned to a related party that provides consulting services for the Company for a total purchase price of $200,000. Mr. Gorlin retained the obligation to purchase 314,286 of the additional shares, for a total purchase price of $550,000.
In exchange for entering into the fourth Amendment, Mr. Gorlin also assigned a portion of the warrant for the right to purchase 112,500 of the 500,000 shares of common stock of the Company from the warrants issued on November 9, 2015.
The purchase of the additional shares of the Company by Mr. Gorlin and the two outside parties was completed in December 2016. The Company received an aggregate of $1,000,000 in exchange for the issuance of an aggregate of 571,429 shares at a price of $1.75 per share.
The Company originally recorded both the convertible debt and the accompanying warrant on a relative fair value basis of approximately $715,000 and $285,000, respectively. The closing price of the Company’s stock on the day prior to issuing the convertible debt was $1.75 per share. See Note 9 for the inputs used to value the warrant as of the respective issue date. Steve Gorlin was also granted piggyback registration rights with respect to the shares of common stock issuable upon conversion of the Note and upon exercise of the warrants.
Short Term Note Payable
On September 13, 2016, the Board of Directors approved a resolution authorizing the Company to obtain a secured nine-month term loan for the principal amount of $1,150,000. In connection therewith, on September 16, 2016, the Company entered into a Unit Purchase Agreement with selected accredited investors whereby the Company had the right to sell units in a private placement to secure the loan.
Original Issuance Discount
The principal face value of the loan is $1,150,000 and was issued with an original issuance discount of $150,000 which resulted in aggregate proceeds of $1,000,000. The loan has a default interest rate of 15% per year and a maturity date of June 16, 2017. The Company is required to repay the principal amount of the loan following the Company’s receipt of any financing in aggregate of
$1,650,000 in the next six months. Additionally, investors have the option to convert the $150,000 original issuance discount, which will accrete over the life of the loan, and principal into future financing or be paid back in cash. The note is also presented net of the issuance costs of $5,000 which will accrete over the life of the note, based on the effective interest method. Accretion expense for the year ended December 31, 2016 was approximately $111,000.
Warrants
Warrants to purchase an aggregate of 200,000 shares of common stock were issued as part of the short term note agreement with a strike price of $1.625 and with an exercise date six months from the closing. The warrants must be exercised within three years from the date of issuance. The Company recorded the proceeds from the loan and the accompanying warrants on a relative fair value basis of approximately $864,000 and $136,000, respectively. The carrying amount has also been reduced by $5,000 related to debt issuance costs. The closing price of the Company’s stock on the day prior to entering into the agreement was $1.50 per share. See Note 9 for the inputs used to value the warrant as of the respective issue date.
The balance of the loan at December 31, 2016 was approximately $970,000, net of discount, and is being accreted to its $1,150,000 face amount over the 9 month period the loan will be outstanding.
|
COMMON STOCK WARRANT |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Warrant | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
COMMON STOCK WARRANT | Fair value measurement valuation techniques, to the extent possible, should maximize the use of observable inputs and minimize the use of unobservable inputs. The Company’s fair value measurements of all warrants are designated as Level 1 since all of the significant inputs are observable and quoted prices were available for the four comparative companies in an active market.
A summary of the Company’s warrant issuance activity and related information as of December 31, 2016 and 2015 is as follows:
The fair value of all warrants issued are determined by using the Black-Scholes-Merton valuation technique and were assigned based on the relative fair value of both the common stock and the warrants issued.
The inputs used in the Black-Scholes-Merton valuation technique to value each of the warrants issued in 2016 and 2015 as of their respective issue dates are as follows:
The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
|
DISCONTINUED OPERATIONS |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discontinued Operations and Disposal Groups [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
DISCONTINUED OPERATIONS | In May 2016, the Board of Directors authorized management to seek buyers for Streamline, the Company’s wholly owned subsidiary acquired in March 2015. In December 2016, the Company entered into a definitive asset purchase agreement pursuant to which the Company agreed to sell all Streamline related assets. The Closing occurred immediately following the execution of the asset purchase agreement on December 7, 2016.
The Company sought additional funds to complete the development and launch of the Company’s primary product, the DenerveX device, and the decision to sell the business unit helped raise necessary funds to fund continuing operations of the Company in a non-dilutive manner to existing shareholders.
The transaction resulted in the immediate receipt of $500,000 in cash, and a $150,000 note receivable due to the Company on or before January 1, 2018.
The terms of the agreement also required that for each of the calendar years ending December 31, 2018 and December 31, 2019, a Contingent Payment in cash equal to five percent (5%) of the total net sales received by the acquiring party from the sale of “IV suspension system” products in excess of 100 units during each Contingent Period. Each such Contingent Payment, of which no value was recorded at December 31, 2016, is payable to the Company by the acquiring party by no later than March 31st of the subsequent year; provided, however, that the total aggregate amount of all Contingent Payments owed by the acquiring party to the Company for all Contingent Periods will not exceed $850,000.
The results of discontinued operations for the current year ended December 31, 2016 includes a disposal loss of approximately $853,000 that was recorded upon consummation of the Streamline divestiture.
The carrying amounts of the major classes of assets of the discontinued operations as of December 31, 2015 were as follows:
The results of the discontinued operations, which represents Streamline’s IV Suspension System (“ISS”), are as follows:
Cash flows from discontinued operations are as follows:
Amortization expense related to the discontinued intangible assets for the year ended December 31, 2016 and 2015 was approximately $190,000 and $426,000, respectively. The recognition of amortization expense related to the discontinued assets ceased in May 2016 when the Board of Directors authorized Management to seek buyers for Streamline.
Depreciation expense amounted to $129 and $171, respectively, for the year ended December 31, 2016 and 2015.
|
IMPAIRMENT OF INTANGIBLE ASSETS AND GOODWILL |
12 Months Ended |
---|---|
Dec. 31, 2016 | |
Intangible Assets | |
IMPAIRMENT OF INTANGIBLE ASSETS AND GOODWILL | As discussed in Note 2, the Company reviews long-lived assets for impairment whenever events or changes in circumstances or occurrence of events suggest impairment exists in accordance with FASB ASC 360.
The Board of Directors decision to seek buyers for Streamline, as discussed in Note 10, was made after management evaluated and determined potential impairment indicators existed relating to poor operating performance as sales are less than previously anticipated. The impact of the operating losses incurred from the Streamline portion of the business contributes significantly to the Company’s operations and financial results. As such, the Company separated the asset groups accordingly between the amortizable intangible assets in developed technology and trademark, and the non-amortizable intangible asset in goodwill, and completed an impairment analysis using a two-step process as described in Note 2.
As a result of the impairment analysis, the Company determined the carrying value of the developed technology exceeded the calculated fair value. Consequently, the Company recognized a write-down of approximately $1,035,714 related to the developed technology in the quarter ended June 30, 2016.
As a result of the impairment analysis, the Company also determined the carrying value of the trademark and goodwill exceeded the calculated fair value. Consequently, impairment losses of $6,455,645 and $548,334, respectively, were recognized in the quarter ended June 30, 2016 related to goodwill and the trademark. |
INCOME TAXES |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Notes to Financial Statements | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
INCOME TAXES | The Company’s policy is to record interest and penalties on uncertain tax positions as a component of income tax expense. As of December 31, 2016, the Company has not incurred any interest or penalties relating to uncertain tax positions.
The Company’s evaluation was performed for the tax years ending December 31, 2015, 2014 and 2013, which remain subject to examination by major tax jurisdictions as of December 31, 2016. The Company does not have any tax years that are no longer subject to U.S. federal, state, and local, or non-US income tax examinations.
For the years ended December 31, 2016 and 2015, the Company has incurred net losses and, therefore, has no current income tax liability and recognized no income tax expense. The net deferred tax asset generated by these losses, which principally consist of start-up costs deferred for income tax purposes, is fully reserved as of December 31, 2016, since it is currently more likely than not that the benefit will not be realized in future periods.
A reconciliation of the statutory federal income tax expense (benefit) to the effective tax is as follows:
Our financial statements contain certain deferred tax assets which have arisen primarily as a result of tax benefits associated with the loss before income taxes incurred, as well as net deferred income tax assets resulting from other temporary differences related to certain reserves and differences between book and tax depreciation and amortization. We record a valuation allowance against our net deferred tax assets when we determine that based on the weight of available evidence, it is more likely than not that our net deferred tax assets will not be realized.
In our evaluation of the weight of available evidence, we considered recent reported losses as negative evidence which carried substantial weight. Therefore, we considered evidence related to the four sources of taxable income, to determine whether such positive evidence outweighed the negative evidence associated with the losses incurred. The positive evidence considered included:
During fiscal 2016 and 2015, we weighed all available positive and negative evidence and concluded the weight of the negative evidence of a cumulative loss continued to outweigh the positive evidence. Based on the conclusions reached, we maintained a full valuation allowance during 2016 and 2015.
Deferred tax assets and liabilities consist of the following at December 31:
The Company is required to file federal income tax returns and state income tax returns in the states of Florida, Georgia and Minnesota. There are no uncertain tax positions at December 31, 2016. The Company has not undergone any tax examinations since inception and is therefore not subject to examination by any applicable tax authorities.
|
RELATED-PARTY TRANSACTIONS |
12 Months Ended |
---|---|
Dec. 31, 2016 | |
Notes to Financial Statements | |
RELATED-PARTY TRANSACTIONS | Royalty Agreement
As further described in Note 4, the Company has a Contribution and Royalty Agreement with Dr. Haufe. No royalties have been paid as of December 31, 2016.
Co-Development Agreement
As further described in Note 7, the Company has a Co-Development Agreement with Dr. Andrews. No royalties have been paid as of December 31, 2016.
Aviation Expense
Periodically the Company may charter general aviation aircraft from TAG Aviation LLC (“TAG”), a company owned by Mr. Jarrett Gorlin. The Company believes that such aircraft charter is on terms no less favorable then it would receive from a third party. General aviation expenses paid to TAG was approximately $26,000 for the years ended December 31, 2016 and 2015.
Operating Lease
As described in Note 7, the Company pays TAG Aviation LLC, (“TAG”), a company owned by Mr. Gorlin, for month to month rental of office space at Dekalb-Peachtree Airport in Atlanta Georgia plus cost of utilities. Rent payments under this arrangement were $1,800 per month through August 31, 2016. Effective September 1, 2016, rent payments under this arrangement increased to $2,000 per month.
Rent expense and utilities cost paid to TAG Aviation amounted to approximately $30,400 and $28,400, respectively, for the years ended December 31, 2016 and 2015.
Consulting Expense
As described in Note 7, the Company paid $55,000 and $420,000, respectively, for the year ended December 31, 2016 and 2015 to a founding stockholder for business advisory services.
Convertible Debt
As more fully described in Note 8, on November 9, 2015, the Company issued a convertible promissory note to Steve Gorlin, a related party, for the principal amount of up to $2,000,000.
|
RESEARCH AND DEVELOPMENT |
12 Months Ended |
---|---|
Dec. 31, 2016 | |
Notes to Financial Statements | |
RESEARCH AND DEVELOPMENT | Devicix Prototype Manufacturing Agreement
In November 2013, the Company accepted a proposal from Devicix, a Minneapolis Minnesota based FDA registered contract medical device designer and developer, to develop a commercially viable prototype of its product that could be used to receive regulatory approval from the FDA and other international agencies for use on humans to relieve pain associated with Facet Joint Syndrome. Through December 31, 2016, we have paid approximately $1,547,000 to Devicix.
The development work commenced in December 2013. The total estimated cost of this work was initially established at $960,000; however, the terms of the proposal allow either the Company or the manufacturer to cancel the development work with 10 days’ notice.
During 2016, the Company incurred approximately $481,000 of expense under this agreement, with approximately $63,000 of the amount in payables at December 31, 2016. During 2015, the Company incurred approximately $399,000 in expenses under the agreement, of which approximately $22,000 was included in accounts payable at December 31, 2015.
DenerveX Generator Manufacturing Agreement
The DenerveX device requires a custom electrocautery generator for power. As described in Note 8, in November 2014, the Company contracted with Bovie to customize one of their existing electrocautery generators for use with DenerveX Device, and then manufacture that unit on a commercial basis once regulatory approval for the DenerveX was obtained.
The Bovie agreement requires a base $295,000 development fee to customize the unit, plus additional amounts if further customization is necessary beyond predetermined estimates. Through December 31, 2016, we have paid approximately $389,000 to Bovie.
Nortech Manufacturing Agreement
In November 2014, we selected Nortech Systems Inc. (“Nortech”), a Minneapolis, Minnesota based FDA registered contract manufacturer, to produce 315 DenerveX devices from the prototype supplied by Devicix for use in final development and clinical trials. The agreement with Nortech includes agreed upon per unit prices for delivery of the devices.
Actual work on development of the final units began in November 2014. During 2016, the Company incurred approximately $455,000 of expense under this agreement, with approximately $61,000 of the amount in payables at December 31, 2016. From inception through December 31, 2016, we have paid approximately $744,000 to Nortech.
For 2015, the Company incurred approximately $273,000 in expenses under the agreement, of which approximately $52,000 was included in accounts payable at December 31, 2015.
|
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLANS |
12 Months Ended |
---|---|
Dec. 31, 2016 | |
Notes to Financial Statements | |
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLANS | The Company incurred net losses of approximately $16,227,000 and $6,523,000 for the years ended December 31, 2016 and 2015, respectively. The Company will continue to incur losses until such time as it can bring a sufficient number of approved products to market and sell them with margins sufficient to offset expenses.
To date, the Company’s sole source of funds has been from the issuance of debt and equity.
As discussed in Note 8, the Company issued a promissory note for $2,000,000 of convertible debt on November 9, 2015 to Steve Gorlin, a director and father of Jarrett Gorlin, the Company’s CEO. The Company received $970,000 in cash and the elimination of $30,000 of directors’ fees upon execution of the agreement. The second installment of $1,000,000 was received in December 2016.
In February 2017, the Company obtained $2,618,060, net of fees, in a private equity financing. The Company will require additional cash in 2017 and is exploring other fundraising options for 2017. However, if the Company is unable to raise sufficient financing in 2017, it could be required to undertake initiatives to conserve its capital resources, including delaying or suspending the development of its technology. These matters raise substantial doubt about the Company’s ability to continue as a going concern.
We may fail to comply with certain listing requirements of the NASDAQ stock market exchange. In August 2016, the Company was notified by NASDAQ of non-compliance with listing rule 5550(b), which requires a minimum $2,500,000 stockholders’ equity for continued listing on the NASDAQ capital market. The Company reported stockholders’ equity of $1,311,796 in our quarterly report on form 10-Q for the quarter ended June 30, 2016. The decline in the Company’s stockholders’ equity was largely a result of the recognition of an impairment loss recorded in our form 10-Q for the quarter ended June 30, 2016 related to the intangible assets of Streamline Inc., the Company’s wholly owned subsidiary acquired in March 2015. The Company requested, and was subsequently granted, an extension until February 27, 2017 to evidence compliance with the stockholders’ equity requirement. Subsequent to the period ended December 31, 2016, the Company completed a capital raise and converted an outstanding note payable into equity. The combination of these transactions enabled the Company to regain compliance and evidence such by the extension deadline. On March 1, 2017, NASDAQ issued a determination that the Company had evidenced compliance with the minimum stockholders’ equity requirement for continued listing on the NASDAQ Capital Market.
NASDAQ will continue to monitor the Company’s ongoing compliance with the stockholders’ equity requirement and, if at the time of our next periodic report the Company does not evidence compliance, we may be subject to delisting.
The financial statements do not include any adjustments to the carrying amounts of its assets or liabilities that might be necessary should the Company be unable to continue as a going concern.
|
SUBSEQUENT EVENTS |
12 Months Ended |
---|---|
Dec. 31, 2016 | |
Notes to Financial Statements | |
SUBSEQUENT EVENTS | As described in Note 6, In November 2016, the Board authorized the issuance of shares of common stock to all Board members, both current and former, in an amount equivalent to $240,000, representing their accrued but unpaid directors’ fees as of December 31, 2016. In January 2017, the Company issued an aggregate of 173,911 shares at $1.38 per share, which was the average closing price of the Company’s stock during 2016, to fulfill this obligation.
On February 9, 2017, the Company entered into a Unit Purchase Agreement with selected accredited investors whereby the Company had the right to sell in a private placement a minimum of $3,000,000 and up to a maximum of $5,000,000 of units. Each Unit had a purchase price of $100,000 and consisted of (i) 96,154 shares of the Company’s common stock, par value $0.001 per share at a purchase price of $1.04 per share, and (ii) a warrant to purchase 48,077 shares of common stock. Each warrant has an initial exercise price of $1.50 per share and is exercisable for a period of five (5) years from the date of issuance.
The offering resulted in gross proceeds of $3,022,000 and resulted in the issuance of an aggregate of 1,631,730 shares of common stock, 12,740 shares of Series A convertible preferred stock and warrants to purchase 2,005,761 shares of common stock. The placement agent collected an aggregate of approximately $350,000 in total fees related to the offering and warrants to purchase an aggregate of 405,577 shares of common stock at a price of $1.50 per share.
Additionally, on February 9, 2017, the Company’s $1,150,000 short term note payable, as discussed in Note 8, was converted into an aggregate of 165,865 shares of common stock and 9,399 shares of series A convertible preferred stock, eliminating the Company’s debt obligation. The debt was converted into shares at $1.04 per share, which was the closing price of the Company’s stock on February 9, 2017. The series A convertible preferred stock is convertible into shares of common stock at $1.04 per share.
As consideration for converting the debt, the noteholders’ agreed to receive common stock in lieu of the 200,000 warrants to purchase common stock that were issued in conjunction with the short term loan, see Note 8.
As a result, the 200,000 warrants were cancelled, and the Company issued to the noteholders’ an aggregate of 200,000 shares of common stock. The closing price of the Company’s stock on February 9, 2017, the day the shares were issued, was $1.04 per share. The fair value of the common stock issued was approximately $208,000. The Company is currently assessing the overall impact the note conversion to stock will have on its consolidated financial statements.
On February 13, 2017, the consulting agreement with the related party providing business consulting services, as discussed in Note 7, was modified to increase the monthly compensation to $10,000 through February 2018. |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) |
12 Months Ended |
---|---|
Dec. 31, 2016 | |
Summary Of Significant Accounting Policies Policies | |
BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION | The accompanying financial statements include the accounts of Medovex Corp. and its wholly-owned subsidiary, Streamline. All intercompany accounts and transactions have been eliminated in consolidation. |
USE OF ESTIMATES | In preparing the financial statements, generally accepted accounting principles in the United States (“U.S. GAAP”) requires disclosure regarding estimates and assumptions used by management that affect the amounts reported in financial statements and accompanying notes. Actual results could differ from those estimates. |
CONCENTRATION OF CREDIT RISK | Financial instruments, which potentially subject the Company to concentrations of credit risk, consist solely of cash. At times throughout the year, the Company may maintain certain bank account balances in excess of FDIC insured limits. At December 31, 2016 and 2015, the Company had cash deposits that exceeded federally insured deposit limits. The Company believes that its funds are deposited in high credit quality financial institutions. The Company has not experienced any losses in such accounts to date and believes it is not exposed to any significant credit risk associated with its cash deposits. |
CASH | The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company’s cash balances at December 31, 2016 and 2015 consists of funds deposited in checking accounts with commercial banks. |
LONG TERM RECEIVABLE | The long term receivable at December 31, 2016 represents the long-term, non-contingent portion of the receivables due from the sale of Streamline which is not due until January 1, 2018. See Note 10. Recording the present value of the receivable at December 31, 2016 and recognizing the subsequent accretion expense over the one year period led to an immaterial amount. |
GOODWILL AND PURCHASED INTANGIBLE ASSETS | Goodwill is reviewed for impairment annually on December 31 or more frequently if changes in circumstances or the occurrence of events suggest impairment exists using a two-step process. In step 1, the fair value of each reporting unit is compared to its carrying value, including goodwill. If the fair value exceeds the carrying value, no further work is required and no impairment loss is recognized. If the carrying value exceeds the fair value, the goodwill of the reporting unit is potentially impaired and the Company would then complete step 2 in order to measure the impairment loss. In step 2, the Company would calculate the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets (including unrecognized intangible assets) of the reporting unit from the fair value of the reporting unit. If the implied fair value of goodwill is less than the carrying value of goodwill, the Company would recognize an impairment loss, in the period identified, equal to the difference. See Note 11.
Other intangible assets consist of developed technology and a trademark. The Company reviews intangible assets for impairment as changes in circumstances or the occurrence of events suggest the remaining value may not be recoverable. See Note 11.
Amortization on the intangibles was provided on a straight-line basis over the estimated useful lives of the assets as follows:
Trademark 5 years Developed technology 7 years
Although we believe that the recorded fair value of our non-financial assets is appropriate at December 31, 2016, these fair values may not be indicative of net realizable value or reflective of future fair values. |
FAIR VALUE MEASUREMENTS | We measure certain non-financial assets at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets and non-amortizing intangible assets for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations.
We use the fair value measurement framework to value these assets and report the fair values in the periods in which they are recorded or written down.
The fair value measurement framework includes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair values in their broad levels. These levels from highest to lowest priority are as follows:
• Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities;
• Level 2: Quoted prices in active markets for similar assets or liabilities or observable prices that are based on inputs not quoted on active markets, but corroborated by market data; and
• Level 3: Unobservable inputs or valuation techniques that are used when little or no market data is available.
The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. We may also engage external advisors to assist us in determining fair value, as appropriate.
Although we believe that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values.
|
PROPERTY AND EQUIPMENT | Property and equipment are stated at cost and are depreciated using the straight-line method over the estimated useful lives of the related assets, generally three to five years. Repairs and maintenance are expensed as incurred. Improvements and betterments, which extend the lives of the assets, are capitalized.
|
LEASES |
The Company recognizes rent expense on a straight-line basis over the term of the lease. The lease term commences on the date the Company takes possession of or controls the physical use of the property. Deferred rent is included in non-current liabilities on the balance sheet.
|
RESEARCH AND DEVELOPMENT | Research and development costs are expensed as incurred. |
ADVERTISING | The Company expenses all advertising costs as incurred. For the years ended December 31, 2016 and 2015, advertising costs were approximately $392,000 and $102,000, respectively.
|
INCOME TAXES | The Company uses the liability method of accounting for income taxes, which requires recognition of temporary differences between financial statement and income tax bases of assets and liabilities, measured by enacted tax rates. A valuation allowance is recorded to reduce deferred tax assets when necessary.
|
STOCK-BASED COMPENSATION | The Company maintains a stock option incentive plan and accounts for stock-based compensation in accordance with ASC 718, Compensation - Stock Compensation. The Company recognizes share-based compensation expense, net of an estimated forfeiture rate, over the requisite service period of the award to employees and directors. As required by fair value provisions of share-based compensation, employee and non-employee share-based compensation expense recognized is calculated over the requisite service period of the awards and reduced for estimated forfeitures.
|
LOSS PER SHARE | Basic loss per share is computed on the basis of the weighted average number of shares outstanding for the reporting period. Diluted loss per share is computed on the basis of the weighted average number of common shares plus dilutive potential common shares outstanding using the treasury stock method. Any potentially dilutive securities are anti- dilutive due to the Company’s net losses. For the years presented, there is no difference between the basic and diluted net loss per share: 3,504,847 warrants and 1,124,900 common stock options outstanding were considered anti-dilutive and excluded for the years presented.
|
BUSINESS COMBINATIONS | The Company completed an acquisition on March 25, 2015. This transaction was recorded using guidelines provided by ASC 805, Business Combinations. Following these guidelines, the consideration paid by MedoveX for Streamline was measured on the date of acquisition. An independent valuation of Streamline was performed using the discounted cash flow method. Based on the estimated value of Streamline, the consideration paid by MedoveX and the tangible assets of Streamline, management determined the intangible portion of the purchase price should be assigned between developed technology, trademark, and goodwill.
|
DISCONTINUED OPERATIONS | As more fully described in Note 10, in May 2016, management was authorized to locate a buyer for Streamline Inc., the Company’s wholly owned subsidiary acquired in March 2015, by the Board of Directors. Streamline’s results of operations have been classified as discontinued operations for all periods presented.
|
RECLASSIFICATION | Some items in the prior period financial statements were reclassified to conform to the current period presentation. Reclassifications had no effect on prior period net income or shareholders’ equity.
|
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS | In August 2014, FASB issued ASU 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern, or ASU 2014-15. ASU 2014-15 explicitly requires a company’s management to assess an entity’s ability to continue as a going concern, and to provide related footnote disclosures in certain circumstances. The new standard will be effective in the first annual period ending after December 15, 2016, although early application is permitted. We do not expect the adoption of this standard to have a material impact on our consolidated statements of financial position, results of operations or cash flows.
In April 2015, FASB issued ASU No. 2015-03, Interest – Imputation of Interest (Subtopic 835-30): Simplifying the presentation of Debt Issuance Costs, to reduce the complexity of having different balance sheet presentation requirements for debt issuance costs and debt discounts and premiums. The guidance requires debt issuance costs related to a recognized debt liability be reported on the balance sheet as a direct deduction from the carrying amount of that debt liability. ASU 2015-03 is effective for public companies for annual reporting periods beginning after December 15, 2015, and interim periods within those fiscal years. The Company has adopted the amendments of ASU 2015-03 effective January 1, 2016.
In November 2015, FASB issued ASU No. 2015-17, Balance Sheet Classification of Deferred Taxes. ASU 2015-17 simplifies the presentation of deferred taxes by requiring deferred tax assets and liabilities be classified as noncurrent on the balance sheet. ASU 2015-17 is effective for public companies for annual reporting periods beginning after December 15, 2016, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. We believe the adoption of this standard will have no material impact on our consolidated statements of financial position, results of operations or cash flows.
In February 2016, FASB issued ASU No. 2016-02, Leases (Topic 842). The core principle of Topic 842 is that a lessee should recognize the assets and liabilities that arise from leases. ASU 2016-02 is effective for public companies for annual reporting periods beginning after December 15, 2018, and interim periods within those fiscal years. The guidance may be adopted prospectively or retrospectively and early adoption is permitted. The Company is currently assessing the impact the adoption of ASU 2016-02 will have on its consolidated financial statements.
|
PROPERTY AND EQUIPMENT (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property And Equipment Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and equipment, net |
|
ACQUISITIONS (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Combinations [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets and liabilities assumed |
|
EQUITY TRANSACTIONS (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Transactions Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Significant assumptions used to estimate the fair value of the equity awards |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of stock option activity |
|
COMMITMENTS (Tables) |
12 Months Ended | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||
Commitments Tables | ||||||||||||||||||||||
Operating leases |
|
|||||||||||||||||||||
Equipment leases |
|
SHORT TERM LIABILITIES (Tables) |
12 Months Ended | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||
Long Term Liabilities Tables | |||||||||||||
Future payments related to the promissory notes |
|
COMMON STOCK WARRANT (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Common Stock Warrant Tables | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant Activity |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assumptions for warrants |
|
DISCONTINUED OPERATIONS (Tables) |
12 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Discontinued Operations Tables | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assets and liabilities of the discontinued operations |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Results of discontinued operations |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash flows from discontinued operations |
|
INCOME TAXES (Tables) |
12 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2016 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Taxes Tables | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Components of Income Tax Expense (Benefit) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Deferred Tax Assets and Liabilities |
|
ORGANIZATION (Details Narrative) |
12 Months Ended |
---|---|
Dec. 31, 2016 | |
State of incorporation | Nevada |
Date of incorporation | Jul. 30, 2013 |
Debride [Member] | |
State of incorporation | Florida |
Date of incorporation | Oct. 01, 2012 |
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) |
12 Months Ended | ||
---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Advertising costs | $ 392,000 | $ 102,000 | |
Common stock options outstanding | 1,124,900 | 380,000 | 60,000 |
Trademarks [Member] | |||
Useful Life | 5 years | ||
DevelopedTechnology | |||
Useful Life | 7 years |
PROPERTY AND EQUIPMENT (Details) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Property and equipment | $ 118,508 | $ 33,375 |
Less accumulated depreciation | (20,918) | (9,651) |
Property and Equipment, net | 97,590 | 23,724 |
Furniture and Fixtures [Member] | ||
Property and equipment | $ 65,987 | 17,100 |
Useful Life | 5 years | |
Computers and software [Member] | ||
Property and equipment | $ 19,928 | 16,275 |
Useful Life | 3 years | |
Leasehold improvements [Member] | ||
Property and equipment | $ 32,593 | $ 0 |
Useful Life | 5 years |
PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Property And Equipment Details Narrative | ||
Depreciation expense | $ 11,267 | $ 6,498 |
ACQUISITIONS (Details) |
Mar. 25, 2015
USD ($)
|
---|---|
Assets acquired | |
Cash | $ 245,174 |
Inventory | 1,878 |
Other assets | 165 |
Developed Technology | 3,000,000 |
Trademark | 700,000 |
Goodwill | 6,455,645 |
Total assets acquired | 402,862 |
Liabilities assumed | |
Accounts payable | 301,940 |
Accrued liabilities | 6,018 |
Notes Payable | 259,938 |
Total | 567,896 |
Net assets assumed | $ 9,834,966 |
EQUITY TRANSACTIONS (Details) - $ / shares |
12 Months Ended | ||
---|---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
Dec. 31, 2014 |
|
Number of options | 1,124,900 | 380,000 | 60,000 |
Jan 6 2016 [Member] | |||
Weighted Fair value of options granted | $ 0.67 | ||
Exercise price | $ 0.95 | ||
Number of options | 214,900 | ||
Expected term (years) | 6 years | ||
Risk-free interest rate | 1.82% | ||
Volatility | 83.00% | ||
Dividend yield | 0.00% | ||
Aug 17 2016 [Member] | |||
Weighted Fair value of options granted | $ 0.91 | ||
Exercise price | $ 1.20 | ||
Number of options | 320,000 | ||
Expected term (years) | 6 years | ||
Risk-free interest rate | 1.28% | ||
Volatility | 75.55% | ||
Dividend yield | 0.00% | ||
Nov 10 2016 [Member] | |||
Weighted Fair value of options granted | $ 1.06 | ||
Exercise price | $ 1.58 | ||
Number of options | 210,000 | ||
Expected term (years) | 6 years | ||
Risk-free interest rate | 1.74% | ||
Volatility | 76.67% | ||
Dividend yield | 0.00% |
EQUITY TRANSACTIONS (Details Narrative) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Compensation expense | $ 776,968 | $ 253,659 |
Nonvested restricted stock | 601,175 | |
Unrecognized stock-based compensation | $ 596,000 | |
Weighted average period | 1 year 8 months 12 days | |
Consultant shares granted | 180,500 | |
Proceeds from private placement | $ 1,300,000 | |
Shares issued in private placement | 1,083,333 | |
Management [Member] | ||
Plan options granted | 294,900 | |
Director [Member] | ||
Plan options granted | 450,000 |
COMMITMENTS (Details) |
Dec. 31, 2016
USD ($)
|
---|---|
Future minimum office lease payments | |
December 31, 2017 | $ 35,000 |
December 31, 2018 | 21,000 |
Total | $ 56,000 |
COMMITMENTS (Details 1) |
Dec. 31, 2016
USD ($)
|
---|---|
Future minimum equipment lease payments | |
December 31, 2017 | $ 2,600 |
December 31, 2018 | 800 |
Total | $ 3,400 |
COMMITMENTS (Details Narrative) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Purchase order | $ 234,000 | $ 484,000 |
Payment of generator development agreement | 102,400 | 181,200 |
TAG Aviation [Member] | ||
Rent/Lease expense | $ 30,400 | $ 28,400 |
SHORT TERM LIABILITIES (Details) |
Dec. 31, 2016
USD ($)
|
---|---|
Long Term Liabilities Details | |
2017 | $ 61,000 |
2018 | 64,000 |
2019 | 45,000 |
Total | $ 170,000 |
SHORT TERM LIABILITIES (Details Narrative) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Long term notes | $ 103,742 | $ 164,726 |
Accretion expense | 111,000 | |
Loan payable | 970,000 | |
Promissory Note | ||
Long term notes | 165,000 | 223,000 |
Payment of interest | $ 10,000 | $ 8,000 |
DISCONTINUED OPERATIONS (Details) |
Dec. 31, 2015
USD ($)
|
---|---|
Current Assets | |
Inventory | $ 1,878 |
Accounts receivable | 33,045 |
Prepaid expenses | 586 |
Total Current Assets Held for Sale | 35,509 |
Property and Equipment, Net | 1,114 |
Trademark, net | 595,000 |
Developed Technology, net | 2,678,571 |
Total Assets Held for Sale | $ 3,310,194 |
DISCONTINUED OPERATIONS (Details 1) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Discontinued Operations and Disposal Groups [Abstract] | ||
Revenues | $ 0 | $ 33,045 |
Cost of Goods Sold | 0 | 25,383 |
Gross Profit | 0 | 7,662 |
Operating Expenses | ||
General and administrative | 218,444 | 439,257 |
Sales & Marketing | 0 | 664 |
Research and development | 59,418 | 72,357 |
Depreciation and amortization | 189,652 | 426,600 |
Disposal loss | 852,864 | 0 |
Impairment loss | 1,584,048 | 0 |
Total Operating Expenses | 2,904,426 | 938,878 |
Operating Loss | (2,904,426) | (931,216) |
Other Expenses | ||
Interest expense | 9,983 | 8,040 |
Total Other Expenses | 9,983 | 8,040 |
Net Loss | $ (2,914,409) | $ (939,256) |
DISCONTINUED OPERATIONS (Details 2) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Discontinued Operations and Disposal Groups [Abstract] | ||
Cash Flows used in Operating Activities | $ (1,295,473) | $ (1,272,992) |
Cash Flows used in Investing Activities | 1,286 | (1,286) |
Cash Flows used in Financing Activities | 0 | (70,109) |
Net Cash Used in Discontinued Operations | $ (1,294,187) | $ (1,344,387) |
DISCONTINUED OPERATIONS (Details Narrative) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Discontinued Operations Details Narrative | ||
Amortization expense related to the discontinued intangible assets | $ 189,652 | $ 426,600 |
INCOME TAXES (Details) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Income Taxes Details 1 | ||
Federal statutory tax rate | 34.00% | 34.00% |
State taxes, net of federal benefit | 4.00% | 4.00% |
Income tax benefit | 38.00% | 38.00% |
Less valuation allowance | (38.00%) | (38.00%) |
Total | 0.00% | 0.00% |
INCOME TAXES (Details 1) - USD ($) |
Dec. 31, 2016 |
Dec. 31, 2015 |
---|---|---|
Deferred Tax Assets: | ||
Start-up costs | $ 5,738,469 | $ 3,528,944 |
Share-based compensation | 203,761 | 57,673 |
Total Deferred Tax Assets | 5,942,230 | 3,586,617 |
Valuation Allowance | (5,942,230) | (3,586,617) |
Net Deferred Tax Asset | $ 0 | $ 0 |
RELATED-PARTY TRANSACTIONS (Details Narrative) - Affiliated Entity [Member] - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Aviation expense | $ 26,000 | $ 26,000 |
Rent expense | 28,400 | 30,400 |
Consulting expense | $ 420,000 | $ 55,000 |
RESEARCH AND DEVELOPMENT (Details Narrative) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Research and Development expenses | $ 1,126,535 | $ 867,822 |
NORTECH MANUFACTURING AGREEMENT [Member] | ||
Research and Development expenses | 455,000 | 273,000 |
Accounts payable | 61,000 | 52,000 |
DEVICIX PROTOTYPE MANUFACTURING AGREEMENT [Member] | ||
Research and Development expenses | 481,000 | 399,000 |
Accounts payable | $ 63,000 | $ 22,000 |
LIQUIDITY, GOING CONCERN AND MANAGEMENT'S PLANS (Details Narrative) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Liquidity Going Concern And Managements Plans Details Narrative | ||
Net loss | $ (16,227,484) | $ (6,523,077) |
TND2R./\% D4('.OU
M=3W(]5JLUV.]N:XGB.MS)!\CAS%2>"S D)7P&%BG(' &PO=V]R:W-H965T4RU8(BM+M&:!!LL@@;,LT%.7 ?.N;$$#K31P31,;-'"5Q@1YI%@PQ%:&
M>,V0& P626I /)0L*!(K1;+V9P9%LJHSRJQOY@/"!5%J)4I71(F1:)>N$OE1
M"J&?FA^N1>@',/:3__Q'F94H6Q,9B7;91XDL0M^+TL +#2(PVZK4T?$#L6O=
MN>-GEA0BA8OXR[;N _C#4\F
MV#J 3P ^ _8Q#QL31>5?A!=Y:LU [-C[3H0G3@X<>U,$9VQ%O$/Q#KV7//E\
MG;)+()IBCF,,7\;,$0S9YQ1\+<61?X#S=?AV5>$VPK?_*+Q9)]BM$NPBP>Z_
M):[%[-\E88N>:K!UG"9'"M.W<9(7WGE@;WE\D[_AX[0_"EO+UI&S\?BRL?^5
M,1Y0RN8*1ZC!#S8;"BH?CC=XMN.8C88WW?2#V/R-\S]02P,$% @ A&E_
M2N69M+^U 0 T@, !D !X;"]W;W)K4?A1=E;LU$[-S[080G
M3H\<>U,%9VQ%O$/Q#KW7DF
X8M$#.0'52!$N&
MRY$IH'\1/H8*(2J@&XIUFU08QZ%J"C=LFD)#=D [+*0X$J=@YR< R.FH%7= (G3[?2)L\D.['AU4!9S*Q%8\'/1<)-%*43 6]I+KO.U#CI)S
M@V!V,9T<:"-_Y Q8%TVC)_FX6/0")UXL, M\GJ[6COEB"IYU/33I*'K5I=(P
MB4U48@K=+LTM\_UQ8N."FGB'E6,IJHJ7:W^"3HF2K((]=*1:SI6^57@)2EM
M5!&ZN]4$>5WOSC2#JAN"^E%8S;BA](&7CT39DBWO:'AG/%HIEX=Q?- MUAN#UIT:&UAO.VH
MHT2];K0'T1"D?E-]HI)+\8I8* O8P=YKTA3@8-OTOA =:-I&2V^T6M%HU.CW
MZX9IPQAZF&['$"W_UXS3Q$'!*@ 24E>">'%E$J>ZKULC/4:+Q^@T]8@],Y5V
MG]2#\ AM,P)8%;4C#'&$X!R&K^UN\/1[;1Z@ZPP L\,I](,#V(WH=+T1W"FT
M^C+"%"NQ3YCGYLDZ&CGO]W@)?=E(^*L^5U+G8(!!KT+F9Y/IZ27ZL]&YC>;F
M>+_V6]=9.+V-[O-'-."8@+S4+TTZ;*1$:<;^&B
4D^>V
M AC% ?VXU%CC^U$DH\-1),/XDB
M5'Q,==Z8H ?6 .Y!'Z%5!A!(HGH$$@9;3K#!TDFQ31\4N3,*[A:)_X GN:VH
MSP1;9T%!*;,H*P0X/#7 \C[LA1MWU;@1\)U%:7QAO(7O;Y81UKE)6*/T)+=2
MB\K]\DHP+"N<^GOSO1(BA_--!QF6EVXP+@R)EM?M2$_YO$S'BZ=JG_?:H%OR
M#K